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ABSTRACT
There are many well-documented differences between males and females regarding
melanoma including incidence rates, presentation, markers of progression, and survival.
A common hypothesis to explain the female survival advantage is that males are less
aware of their skin, resulting in thicker lesions at diagnosis, and ultimately poorer
survival. However, there are also multiple hypotheses attributing the female survival
advantage to biological differences between males and females, mostly regarding sexsteroid hormones. Sex has been identified as an independent prognostic marker in
multiple studies, supporting the hypothesis that melanoma progression varies between
men and women. Despite these findings, stratifying by sex in melanoma studies is
uncommon. Here we present four studies investigating both behavioral and biological
differences as they relate to Breslow thickness and melanoma survival in analyses
stratified by sex.
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We found that different factors contribute to Breslow thickness and survival between
males and females. Our results suggest that UV exposure is associated with increased
male survival independent of Breslow thickness. UV exposure is associated with
decreased Breslow thickness in females, but was not significant in the survival models
suggesting that the effect was encompassed by Breslow thickness in the survival model.
Furthermore, skin awareness was associated with increased survival and decreased
Breslow thickness in females, but not in males.
We also identified multiple SNPs in DNA repair and immune response genes that
were associated with Breslow thickness, and interacted with UV exposures to modify
Breslow thickness. Importantly, there was only one SNP that overlapped in the male and
female analyses, and the analysis of SNPs in the overall population was not
representative of the analyses stratified by sex.
Our results may help explain previous inconsistencies in the literature regarding UV
exposure impact on Breslow thickness and survival. Furthermore, these studies provide a
good foundation for further investigating the role of UV exposures in the female survival
advantage. Finally, we have demonstrated the importance of analyses stratified by sex in
the study of melanoma.
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CHAPTER ONE:
INTRODUCTION

1

1.1 Melanoma background:
Melanoma is a cancer that arises from melanocytes, which are the melanin

producing cells that reside in the basal layer of the epidermis [1]. Other skin

cancers, such as basal cell carcinoma and squamous cell carcinoma, arise from the

keratinocytes in the epidermis [1]. Of these different types of skin cancer, melanoma
is the most aggressive and the most deadly—melanoma accounts for less than two

percent of skin cancers, but more than 75% of skin cancer deaths [2]. The incidence
of melanoma has been steadily increasing over the last ten years, perhaps partially
due to the increase in indoor tanning, and is currently the most common cancer
among young adults aged 25-29 [3]. For 2015, it is estimated that there will be
73,870 new cases of melanoma and 9,940 deaths from melanoma [2].

There are several host factors that have been associated with melanoma risk

including number of nevi, phenotypic index (hair color/eye color/tannability),

weakened immune system, older age, sex, and genetic factors such as Xeroderma
Pigmentosum (which affects DNA repair capacity) [4].

While there are multiple known host risk factors melanoma, there are few

known environmental risk factors. The only well-studied environmental risk factor

is ultraviolet (UV) radiation, such as that during sun exposure or indoor tanning. UV
exposure, including UVA and UVB wavelengths, is thought to lead to melanoma

because of its ability to cause DNA damage [5]. While there is some overlap, UVA
and UVB radiation largely cause different types of DNA damage and are

consequently repaired by different DNA repair mechanisms: base excision repair
(BER) and nucleotide excision repair (NER) respectively [5,6]. Interestingly, the
2

UVA/UVB ratio and dose is different in sunlight than in tanning beds, and in fact,

varies from tanning bed to tanning bed [7]. Furthermore, biological consequences

resulting from UV exposure, such as vitamin D production and immunosuppression,
may also influence melanoma risk [8–10].

1.2 Melanoma progression:

Once a patient has been diagnosed with melanoma, the best prognostic indicator

is Breslow thickness, which is the depth of the lesion in millimeters from the

granular layer of the epidermis to the deepest point [11]. Breslow thickness, along

with ulceration and mitoses, make up the “tumor” classification of the tumor, nodes,
and metastasis (TNM) staging system developed by the American Joint Committee
on Cancer (AJCC) [12]. Breslow thickness also correlates with metastases; that is,

the thicker the lesion is, the more likely it is that the melanoma has broken through

basal layer of the epidermis and spread to lymph nodes or a distant site [11,12]. The
5-year survival rate for localized melanoma is 98.3%, but the survival rate

dramatically decreases for nodal metastasis (63%) and distant metastasis (16.6%)
[12].

Other variables, besides those included in the TNM staging system, have been

identified as prognostic indicators for melanoma. Histologic variables associated
with better prognosis are low Clark level (measurement of melanoma thickness

determined by the layer of skin the lesion has reached), absent tumor vascularity,
absent vascular invasion, absent microsatellites, absent regression of the primary
tumor, and present tumor infiltrating lymphocytes (TILs) [4]. Clinical variables
3

associated with better prognosis include younger age, female sex, lesions located on
extremities, and normal serum lactose dehydrogenase (LDH) levels (140-280
units/L) [4].

It is unclear exactly how melanoma progresses, but one theory is that it

progresses in a linear fashion, and there is variation in the rate of growth between

individuals [13]. Clark and colleagues developed this theory in 1989, and it outlines
six histological changes from development of a benign nevus to metastatic

melanoma [14]. Step 4 is the onset of melanoma and is called the radial growth

phase (RGP) [14]. RGP is associated with superficial spreading melanoma (SSM), the
histologic subtype that accounts for approximately 65% of melanomas [13]. Step 5

is the vertical growth of the melanoma that will allow it to eventually break through
the basal layer of the skin and metastasize—this is called the vertical growth phase
(VGP) [14]. Vertical growth phase is associated with nodular melanoma (NM), the
histologic subtype that accounts for approximately 20% of melanomas [13].

Recently, Greenwald et al. challenged the linear progression model by reviewing
evidence that SSM and NM are actually distinct biological entities [15]. To date,

histologic subtype has not been implemented into the AJCC staging system or
clinical practices [12,15].

1.3 Sex differences in melanoma:
1.3.1 Incidence

There are well-documented differences between males and females in

melanoma incidence. SEER reports that men are 1.7 times more likely to develop
4

melanoma [16]. The incidence rate is also affected by age [16]. Women are slightly

more likely than men to develop melanoma before age 50. Following age 50, there is
a crossover in incidence rates, and the incidence rate for men drastically increases
[16]. Interestingly, one-third of melanomas diagnosed in women are during

childbearing years, and there is an increased risk of developing melanoma during
pregnancy, implicating estrogen in the development of melanoma [17].

Furthermore, in the Netherlands, use of oral contraceptives and hormone

replacement therapy has been associated with an increase in melanoma incidence in
women [18]. These findings remain controversial as other studies have reported

that use of oral contraceptives and hormone replacement therapy does not impact
melanoma risk [19].
1.3.2 Presentation

Melanoma presentation also varies between men and women. As discussed

above, men are more likely to present with melanoma at an older age [16].

Furthermore, men are more likely to develop melanoma on their head, neck, or
trunk, whereas the majority of melanomas in women are on their extremities,

particularly their legs [20,21]. Nodular melanomas, which are the most aggressive

histologic subtype, generally arise on the trunk and are more common in men [22].

Men also tend to have thicker lesions that are more frequently ulcerated compared
to women [23].

5

1.3.3 Progression

While studying the specific progression of melanoma can prove difficult, there

are multiple studies suggesting that melanomas in males are inherently more

aggressive, and thus progress more quickly, than melanomas in females. Regarding

hormones and melanoma progression, decreased Breslow thickness in women who
use oral contraceptive or hormone replacement therapy has been observed in a

univariable model, but was not significant in the multivariable model [24]. In 2009,
Liu et al. showed that melanomas in males have an increased rate of growth

compared to females [25]. Another study showed that melanomas in females are
less likely to develop regional or distant metastases [26]. Furthermore, even

following metastasis, women have significantly better survival compared to men

[26]. Finally, women with stage III and IV melanoma also have better relapse-free
survival compared to men [27]. Taken together, these results demonstrate that

melanomas in males are more likely to progress, and more likely to cause death

following progression, compared to females. Therefore, it is possible that there are
different biological factors (potentially hormones and medications affecting

hormones) mediating melanoma progression in males compared to females.

1.3.4 Survival

The female survival advantage was observed as early as 1959 when White et al.

reported that females have an increased 5-year melanoma survival rate compared
to males [28]. In 1980, Rampen showed that women lived longer following first

evidence of metastasis than men [29]. Additionally, Shaw et al. showed that women
6

with thicker lesions had better survival than men with thick lesions [30]. More

recently, Joosse et al. has showed that sex is an independent prognostic indicator in
stage I/II melanoma, as well as in stage III/IV melanoma [27,31]. Finally,

Khosrotehrani et al. reported that females have superior survival across all stages of
melanoma, and that the female survival advantage dissipated with increasing age
[32].

Age also affects survival; the median age at death is 69 years, and the highest

percent of melanoma deaths are aged 75-84 [16]. While age impacts the female

survival advantage and older men are more likely to develop melanoma, age does
not appear to entirely account for the sex discrepancy in melanoma survival. In

2009, Gamba et al. investigated survival in young men aged 15-39 compared to age-

matched women [33]. They found that young men are twice as likely to die from

melanoma than young women, even when they had thin (<1.00mm) lesions [33].

The complicated role of age melanoma survival implicates sex steroid hormones,

particularly estrogen and its receptors, in melanoma survival. As age increases, the
female survival advantage dissipates [34]. Furthermore, post-menopausal women

have poorer survival than pre-menopausal women [34]. Because levels of estrogen

and its receptors decrease following menopause, it is possible that hormones drive
the age-dependent changes in female survival, as well as the sex differences in
survival [29,35].

7

1.4 Estrogen and its receptors in normal skin and melanoma:
1.4.1 Normal skin

There are three known estrogen receptors: ERα, ERβ, and GPER [36]. ERα and

ERβ are the canonical estrogen receptors that act primarily as transcription factors

[36]. GPER is a newly discovered estrogen receptor that resides in the endoplasmic

reticulum and acts primarily through rapid response signaling [36]. There are three
estrogens that can activate estrogen receptors: estrone (E1), estradiol (E2 or 17βestradiol), and estriol (E3) [37]. For women, E2 is most common pre-menopause
and E1 is most common post-menopause [37]. It is unclear which estrogen is the

most common in males, although it is likely to be E2 since it can be synthesized from
testosterone [38]. Both males and females can synthesize estrogens in their skin
[37].

While both of the traditional estrogen receptors are expressed in the skin, ERβ is

more prevalent [35]. Men also express ERα and ERβ in their skin, but the expression
is lower compared to females [39]. To date, the role of GPER in skin, and melanoma
in particular, has not been published. Preliminary studies in our group show that
GPER is expressed in melanoma (unpublished work). As menopause occurs and

estrogen levels decrease, there are multiple effects on the skin including dryness,

wrinkling, decrease in collagen and skin thickness, and delayed wound healing [35].

8

1.4.2 Melanoma

The role of estrogen receptors in cancers is context-dependent; however, in

general, ERα promotes proliferation, while ERβ inhibits proliferation [40,41]. The

exact mechanism of estrogen and its receptors in melanoma is not well defined. Di
Giorgi et al. showed that decreased ERβ protein expression was associated with
thicker lesions [39]. Furthermore, they showed that a decrease in ERα and ERβ

mRNA levels were also associated with thicker lesions [39]. Similarly, Richardson et
al. showed that in vitro exposure to estrone or estradiol, two endogenous estrogens,
inhibits invasion [42]. Interestingly, the same group also reported that circulating

estrone decreases with melanoma progression in male mice, but not in female mice,
further implicating estrogens in the female survival advantage [42].

With the discovery of estrogen receptor expression in melanomas, there has

been much debate over whether Tamoxifen, an anti-estrogen therapeutic, would be
effective in treating melanoma. The results, summarized in a meta-analysis by

Beguerie et al, have been complex and controversial [43]. Overall, Beguerie et al.

found that Tamoxifen is usually used as an adjuvant therapy in stage III/IV

melanoma, and works better in females [43]. However, they did not report an

improvement in mortality from melanoma [43]. Interestingly, in other cancers,
Tamoxifen is used to treat estrogen-dependent tumors, such as in ERα positive

breast cancer. The female survival advantage in melanoma suggests that estrogen

has an anti-tumor role in melanoma; therefore, it is not surprising that Tamoxifen
does not have an overwhelming effect in the treatment of melanoma.
9

1.5 Androgen and its receptors in normal skin and melanoma
1.5.1 Normal skin

Androgen receptors are also in the skin, including the epidermis and the dermis,

although they are less prevalent than ERβ [44]. There are four androgens that can
activate the androgen receptor including dehydroepiandrosterone sulfate,

androstenedione, testosterone, and 5α-dihydrotestosterone [45]. Interestingly,

testosterone (women only) and 5α-dihydrotestosterone are also synthesized in the
skin [45]. Androgens and its receptor are involved in multiple normal skin

processes including sebaceous gland growth and differentiation, hair growth,
epidermal barrier homeostasis, and wound healing [45].
1.5.2 Melanoma

A role for androgens in progression of melanomas was hypothesized as early as

1980 [46]. However, to date, expression of androgen receptors in melanoma tissues
has not been identified [47]. Interestingly, an androgen-dependent protein,

Apolipoprotein D, is expressed in melanomas, particularly nodular melanomas, but
not normal skin [48]. Additionally, one study showed that blocking androgen

improved patient response to a melanoma vaccine [49]. Therefore, the possibility
that androgens play a role in melanoma cannot be entirely ruled out.
1.6 Behavioral differences between men and women:
1.6.1 Skin awareness
10

Early detection of melanoma is important to survival [16]. In 2005, Berwick et al.

showed that skin awareness is associated with increased survival from melanoma,
possibly due to earlier diagnosis [50]. It has also been shown that skin self-

examination (SSE) reduces the risk of having a thicker tumor at diagnosis [51]. Men
are less likely to be aware of their skin or perform skin self-examinations compared

to women [52]. This finding contributes to the common hypothesis that men have
increased Breslow thickness at diagnosis, and therefore have poorer survival

because they are less aware of their skin. However, there is controversy as another
study showed that performing SSE is associated with thicker tumors when

compared with spouse, general physician, or dermatologist examination [22].

Furthermore, it is likely that nodular melanoma, which has a poorer prognosis and

occurs more frequently in men than in women, is harder to detect by SSE because it
often does not adhere to the SSE guidelines of a suspicious lesion [22]. Men have
also been shown to have an increased rate of growth in their melanoma lesions,

indicating that their melanomas may be more aggressive by nature [25]. Finally,
Joosse et al. demonstrated that sex is an independent prognostic indicator for

melanoma survival in stage I/II and stage III/IV melanomas, even with Breslow

thickness included in the multivariable model [27,31]. These results suggest that

skin awareness and skin self-examination only partially explain the female survival
advantage.
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1.6.2 UV exposure

It is well documented that UV exposure is a causative factor of melanoma. UV

exposure has also been associated with increased survival and thinner lesions, but
has not been studied as thoroughly, and the associations have been inconsistent

[50,53]. Men and women have different behaviors regarding UV exposure, which
may influence the development and progression of their disease, and therefore

survival from melanoma [54,55]. Specifically, women are more likely to indoor tan

and sunbathe to acquire a tan, but they are also more likely to wear sun protection

during ambient UV exposure [54,55]. Men are more likely to work outdoors and are
less likely to protect their skin from the sun [54].
1.7 Biological impact from behaviors:

1.7.1 Relevance of behaviors regarding biology

Skin awareness and SSE have an impact Breslow thicknes and melanoma

survival due to early detection, but the action itself is not likely to affect biological
processes. However, UV exposure interacts with multiple biological systems and
their downstream effectors including Vitamin D, immune response, and DNA

damage/repair, which may impact outcomes for melanoma. Not only are there sex

differences in UV exposure behaviors, there is evidence for sex differences in these
biological systems.
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1.7.2 Vitamin D

UV exposure induces production of the hormone Vitamin D [56]. 7-

dehydrocholesterol, the pro-vitamin to Vitamin D, resides in the epidermis and

requires photoactivation by UVB [56]. Classically, Vitamin D is known for its ability
to increase calcium and phosphorus absorption and impact skeletal development
[56]. Extreme Vitamin D deficiencies result in rickets, a childhood disease that
causes the bones to soften, resulting in debilitating skeletal deformities [56].

Vitamin D has also has a role in immune response, blood cell formation, and cell
growth regulation [8,9].

More recently, epidemiological studies have associated Vitamin D with other

diseases, including autoimmune diseases, cardiovascular disease, susceptibility to

infections, and cancer [9,56,57]. However, it has been postulated that Vitamin D is

merely a biomarker for overall health, and therefore is correlated with diseases, but
does not have a direct impact [9]. Nonetheless, Vitamin D in melanoma is

particularly interesting because UV exposure, a risk factor for melanoma, induces

Vitamin D production, a potentially protective factor.

Vitamin D has multiple cellular effects that appear to inhibit proliferation

through both genomic and non-genomic effects [58]. The non-genomic effects of

Vitamin D are not well understood; however, there are some insights to the genomic
effects [58]. The Vitamin D receptor (VDR) is a nuclear receptor that, following

binding by its ligand Vitamin D, binds to Vitamin D response elements in genes to
modulate transcription [58]. VDR acts as a transcription factor for and increases
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expression of multiple genes including: osteopontin, RANKL, Calbindin-9k, IGFBP

and β3 integrin [57]. Furthermore, it is responsible for downregulation of EGFR, a

pathway that is constitutively active in melanomas with a BRAF or NRAS mutation
[9,59]. Concomitantly, epidemiological studies investigating melanoma outcomes
have consistently associated Vitamin D with decreased Breslow thickness and
improved survival [9,60].

Sex differences in the effects of Vitamin D have been observed as early as 1981,

when Thomas and Forte reported differences in longevity of male and female rats
that were on a Vitamin D deficient diet [61]. In 2012, a study in patients with

multiple sclerosis showed that Vitamin D and estrogen (E2) have a functional

synergy that improves outcomes for women [62]. Another study showed obese men
are 40% more likely to have a Vitamin D deficiency than obese women [63]. Taken
together, these results suggest that there are sex differences in consumption,

synthesis, and effect of Vitamin D. Therefore, there may be an interaction between
UV exposure and Vitamin D that contributes to the female survival advantage.
1.7.3 Immune response

Melanoma is known to be an immunogenic cancer, as evidenced by primary

tumor regression and lymphocytic infiltration [64,65]. In fact, therapeutic

development for melanoma often focuses on exploiting the immune response [65].

Unfortunately, melanoma often evades the immune response via downregulation of
antigenic molecules or secretion of immunosuppressive cytokines [64,65].
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UV exposure can also influence the immune response via Vitamin D, as discussed

above, and other immune modulators [8]. In 1974, Kripke reported that tumors

developed in mice exposed to UV due to immunosuppressive effects of UV exposure
[66]. Since then, it has been discovered that many immune factors are induced by

UV exposure including: PGE2, IL-10, IL-6, TNF, platelet activating factor, and nerve

growth factor [8]. It has also been observed that responses to acute and chronic UV

exposures are different [67]. That is, acute UV exposure causes immunosuppression,
but chronic UV exposure induces photoadaptation and photoprotection, diminishing
the responses observed in acute exposures [67]. The understanding of

photoadaptation and photoprotection regarding immune response to UV exposures
is limited, but these processes may contribute to explaining the role of UV exposure
in melanoma progression and survival [8,67]. Importantly, behaviors leading to
acute and chronic UV exposure vary between men and women [54,55].

There are also sex differences in the immune response. In 1985, Ansar et al.

published a review stating that women have more vigorous immune responses, are
more resistant to infections, and have a higher incidence of autoimmune disease
[68]. Furthermore, it has become evident that estrogen, androgens, and

progesterone influence both innate and adaptive immune responses in different

ways [69]. For example, estrogen appears to have an anti-inflammatory effect on
neutrophils, an innate immune cell, while progesterone appears to have a pro-

inflammatory effect [69]. Overall, the effect of hormones on the immune response is
complex and varies with hormones levels in individuals [69]. Because there is an

effect of UV exposures and hormones on the immune system, and both of these vary
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between the sexes, immune response is an important consideration in the female
survival advantage, especially given the immunogenic nature of melanoma.
1.7.4 DNA damage and repair

As discussed previously, UV exposure induces oxidative damage, which is

usually repaired by BER, along with cyclobutane pyrimidine dimers (CPDs) and 6-4

photoproducts, which are usually repaired by NER [5,6]. DNA damage caused by UV
exposures has been implicated in melanomagenesis for decades. However, recently,
it has been hypothesized that DNA repair is also important for melanoma survival.
In 2008, Kauffmann et al. reported that four NER genes and two BER genes were
overexpressed in primary melanomas [70]. Furthermore, as Breslow thickness

increases, so does the expression of DNA repair genes [70]. Additionally, in 2009,

Emmert and Kraemer suggested that aggressive melanomas require the ability to
repair DNA quickly to allow for replication [71]. Similar to NER, increased MGMT

(O-6 methylguanine DNA-methyltransferase) repair, which is a direct reversal DNA
repair pathway that repairs alkylation damage, was associated with melanoma

survival [72]. Inhibition of MGMT via promoter methylation has been shown to

increase response to chemotherapeutic temozolomide and prolong progression-free

survival [72].

There are reported sex differences in DNA damage and repair. In 2011, Slyskova

et al. reported that in a study of healthy participants, women had more DNA damage
[73]. Furthermore, in 2014, Slyskova et al. demonstrated that women have
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decreased BER and NER capacity compared to men [74]. To date, the cause of NER
and BER variations between the sexes has not been discovered.

There are also sex differences in the MGMT repair pathway. In a study on non-

small cell lung cancer, MGMT promoter methylation varied by sex and smoking

status [75]. In colon cancer, MGMT promoter methylation was increased in the right
(ascending) colon of women [76]. These differences between cancers indicate that

MGMT methylation is context-dependent, and perhaps influenced by environmental
factors. Finally, one study reported that MGMT is a negative regulator of ERα

transcription following treatment with an alkylating agent [77]. Taken together,

these studies suggest that MGMT may be important to sex differences in melanoma
survival, especially in for patients treated with alkylating therapeutics.

There is also evidence that DNA damage and repair induces an immune response

[8]. Since immune response varies between the sexes, as discussed above, it is

possible that DNA damage and repair induces an immune response differently in
males compared to females. Therefore, when evaluating the female survival

advantage in melanoma, it is important to consider the potential role of DNA
damage and repair.

1.8 Single Nucleotide Polymorphisms (SNPs):
1.8.1 Definition and functionality of SNPs

Single nucleotide polymorphisms (SNPs) are inherited nucleotide variations in

the germline DNA and are the most common form of genetic variation. The majority
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of SNPs are located in intronic regions of genes, which often makes defining the

potential biological importance of a SNP difficult [78,79]. There are a few known

ways that intronic SNPs may have a direct biological impact. First, the SNP could be

located in a regulatory element such as a transcriptional promoter or enhancer [79].
Second, the SNP could be located in small non-coding RNA that affects transcription

of another gene [79]. Third, the SNP could be located in or near a splice site, thereby
affecting alternative splicing [79].

While it is possible that an intronic SNP has a functional impact on gene

expression, it is more likely that the SNP is in linkage disequilibrium (LD) with a

SNP that is functional [78,80,81]. That is, the two SNPs, one of which is functional,

have a nonrandom association [81]. Unfortunately, it can be challenging to correctly
identify which SNPs are in LD [81]. Because the functional SNP cannot always be

identified, SNPs can be helpful in identifying genomic loci of interest in a particular
disease [80,81].

Furthermore, when designing a candidate gene SNP study, including exonic SNPs

can be limiting because they often have a minor allele frequency (MAF) less than
0.05, which is generally the inclusion criteria in a SNP analysis due to a need for

adequate statistical power [78]. A solution to this problem is to include an intronic
tagging SNP—a SNP in an intron that is known to be in LD with other SNPs within

the gene [78,80]. Intronic tagging SNPs generally have a higher MAF, and allow for

adequate coverage in the evaluation of the gene of interest [78]. While tagging SNPs
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have high frequency in the genome, they are less likely to have a strong association
with disease risk and/or outcomes [78].

1.8.2 Gene-environment interactions

Single, high penetrance mutations are rare, and cause only a small proportion of

cancers [78,80,82]. Furthermore, genetic variation within disease is complex, as
evidenced by multiple low penetrance variants influencing phenotypes and

outcomes [78,80,82]. As such, it has become evident that focusing only on the

genetic variation within diseases is a reductionist approach and does not entirely
account for disease phenotype or outcome [82–84]. One way to address this

complexity is to investigate interactions between genetic factors, such as SNPs, and
environmental exposures [83,85]. Gene-environment interactions allow

researchers to explore multifactorial diseases while taking into consideration low
penetrance variants and environmental exposures [83,85].
1.8.3 Previous associations with melanoma

A plethora of SNP studies in melanoma have previously been published. Here

we will summarize the most relevant findings. In 2012, Ward et al. summarized

SNPs associated with melanoma risk and prognosis, and reported SNP associations
in 8 immune response genes and 11 DNA repair genes [86].

The immune response SNPs summarized by Ward et al. were associated with

Breslow thickness and melanoma survival [86]. One SNP in IL-10 (-1082AA) has
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been consistently associated with increased Breslow thickness and poor survival

outcomes. Another SNP in IFNγ (-874AT) was associated with increased response
to therapy and overall survival [86]. In 2003, Howell et al. found that a SNP in IL-1β
was associated with thinner lesions [87]. The group also investigated SNPs in

cytokines in association with melanoma susceptibility, but did not identify any
significant SNPs [88].

SNPs in DNA repair genes have been associated with both melanoma risk and

survival, particularly SNPs in NER and MGMT genes [71,89–96]. As Emmert and

Kraemer suggested, it is possible that increased DNA repair capacity is protective

against developing melanoma, but is detrimental to fighting the disease following

development [71]. As such, SNPs may be an important marker of inter-individual

variation in DNA repair capacity. Furthermore, DNA repair SNPs have been shown

to interact with indoor tanning to modify melanoma risk [95]. To date, there are no
studies investigating DNA repair SNP interactions with UV exposures impact on
Breslow thickness or melanoma survival.

Regarding sex differences in SNP studies, a SNP in MDM2, an E3 ubiquitin ligase

that targets p53 for proteasomal degradation, was associated with melanoma risk in
women, but no association was found in men [97]. Kocarnik et al. reported that men
with a SNP in SLC45A2, a gene involved in estrogen-induced expression of

tyrosinase, have an increased risk of developing melanoma when compared to
women with the same genotype [98].

1.9 Rationale, hypothesis, and specific aims:
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1.9.1 Rationale

Multiple studies have been published identifying sex as an independent

prognostic indicator, providing further evidence that melanomas diagnosed in
males are inherently more aggressive, and perhaps biologically different, than

melanomas diagnosed in females. Despite this, it is uncommon to stratify analyses
by sex. Here we aimed to investigate behavioral and biological factors in sex-

stratified analyses to provide insight to the female survival advantage. A secondary
goal of this project was to demonstrate that analyses for the overall population
adjusted by sex are not representative of sex-stratified analyses.
1.9.2 Hypothesis

Our hypothesis was that behavioral and biological factors would differentially

impact survival and Breslow thickness in males compared to females. We tested our
hypothesis through following specific aims:
1.9.3 Specific aim 1

Determine the contribution of behavioral and biological factors melanoma

survival in males compared to females.

Hypothesis: Behavioral and biological variables will be differentially associated

with melanoma survival in males compared to females, while histopathological
variables will be comparable.
1.9.4 Specific Aim 2
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Determine the contribution of behavioral and biological factors to Breslow

thickness in males compared to females.

Hypothesis: UV exposures, histopathological, and biological variables will be

comparable between sexes, while skin awareness will be associated with decrease
Breslow thickness in females.
1.9.5 Specific Aim 3

Evaluate the association of SNPs in DNA repair and immune response genes with

Breslow thickness, independently in males and females.

Hypothesis: Distinct SNPs in DNA repair and immune response genes will be

associated with Breslow thickness in males compared to females, and the SNPs that
overlap between sexes will have differential odds ratios.
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CHAPTER TWO:
FACTORS CONTRIBUTING TO SURVIVAL FROM MELANOMA VARY BETWEEN
MALES AND FEMALES
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2.1 Abstract:
Background: A female survival advantage has been observed in melanoma for

many decades. Despite this, investigating the role of sex in melanoma survival using
a stratified analysis is uncommon. We sought to determine which behavioral and
biological factors contributed to 5-year and 15-year melanoma survival in males

compared to females.

Methods: Multivariable survival analyses and Cox regression were performed

using cases from a population-based case-control study of melanoma patients
(males n=283, females n=260). All analyses were stratified by sex.

Results: In our model including all cases, sex was not an independent prognostic

indicator. We found that UV exposures are inversely associated with mortality in

males, particularly in the 5-year models, but are not associated with female survival.
We also found that skin awareness was inversely associated with melanoma

survival in females, but was not associated with survival in males. Breslow thickness
was the only consistent predictor of survival at both 5 and 15 years follow-up.

However, men have poorer survival from thick lesions (>2.00mm) than women with
thick lesions. Menopause also appears to pay a role in female survival.

Conclusions: Despite the fact that sex was not an independent prognostic

indicator in the model for all cases, we found that varying behavioral and

histopathological variables contribute to melanoma survival when analyses were
stratified by sex.

24

Impact: These findings support the notion that males have more aggressive

melanomas that are biologically distinct from female melanomas, and highlight the
need for sex-stratification in future melanoma studies.
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2.2 Introduction:
Melanoma accounts for less than two percent of skin cancers, but more than 75% of
skin cancer deaths [2]. The best prognostic indicator for melanoma is Breslow

thickness, but many other histopathological variables such as ulceration, mitoses,

and anatomic site have also consistently been associated with melanoma prognosis
[4]. Behavioral variables such as UV exposure, self-skin examination (SSE), skin

awareness, and physician visits, have also been associated with survival although
less consistently [50,99,100].

Interestingly, a female survival advantage in melanoma has been observed for

many years [4]. Multiple studies report evidence that melanomas in males are more
aggressive than melanomas in females [25–27,31,101]. Two European studies have
shown that sex is an independent prognostic indicator for melanoma regardless of

the stage at diagnosis [27,31]. Khosroteharani et al. (2015) also found that females

have better survival than males across all tumor stages [32].Using data from the US

Surveillance, Epidemiology, and End Results (SEER) study, Fisher and Geller (2013)
reported that men between the ages of 15 and 39 are 55% more likely to die of

melanoma than women in the same age group [101]. A study by Liu et al. (2006)
reported an increased rate of growth in melanomas diagnosed in males when
compared with females [25]. Finally, de Vries et al. (2011) found that men’s

melanomas are more likely to metastasize [26]. Taken together, these findings
suggest that melanomas progress differently between males and females.
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Despite these apparent differences in melanoma biology, stratifying survival

analyses by sex is uncommon. There are multiple hypotheses regarding the female
survival advantage including hormonal influences on the immune system, reactive

oxygen species, vitamin D metabolism, and X and Y chromosome-specific oncogene
expression [102]. Behaviors such as UV exposure can impact these biological
differences, and may influence melanoma progression differently in males

compared to females [101]. Therefore, we sought to determine factors that would

predict short-term (5 year) and long-term (15 year) survival of melanoma patients,

and hypothesized that different behavioral, histopathological, and hormonal factors
would contribute to survival of males compared to females.
2.3 Methods:
2.3.1 Subjects

This population-based study has been described previously [99]. Briefly, cases

were identified through a rapid case ascertainment system functioning as an agent
of the Connecticut Tumor Registry, and consisted of 650 non-Hispanic whites
residing in Connecticut when they were diagnosed with invasive cutaneous

melanoma between January 15, 1987 and May 15, 1989. Follow-up data for vital

status and cause of death were collected at approximately 5 and 15 years (1994 and
2006 respectively), via personal contact (mail/telephone/physicians), the

Connecticut Tumor Registry, or the National Death Index. For our analysis, 107
participants with missing information were excluded, leaving 543 subjects for
analysis.
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2.3.2 Categorization of Variables

We developed several summary variables. Definitions of all summary variables

can be found in Supplementary Data 1. Here we include the most salient summary
variables.

Histopathology was reviewed by RLB. Breslow thickness was evaluated both

continuously and also categorized as thin (<1.00mm), intermediate (1.00-1.99mm),

and thick (2.00mm+), adhering to the AJCC staging guidelines for melanoma [12].
We also combined Breslow thickness and sex (Breslow-sex) into six categories
representing sex by thin, intermediate, and thick lesions.

Reported number of sunburns was collapsed into ever/never categorization.

Intermittent sun exposure was created and categorized as high/low and was

previously described; this variable was also previously referred to as “lifetime sun
exposure” and “recreational sun exposure” [50,99,103]. Skin awareness was

reported as multiple levels including ‘unaware’, ‘aware of skin cosmetically’, ‘aware

of changes in skin’, ‘aware of abnormalities in skin’, and ‘aware of other factors’. We
re-categorized this variable to represent unaware or aware. A skin examination
index variable was created as either ‘yes’ if a participant’s skin had ever been
examined by themselves, a spouse, or a doctor, or ’no’ if they had not been

examined. Females participating in the study were asked to report their menopause

status, which was collapsed into a two-category variable indicating pre-menopausal

and post-menopausal. We also created a variable, for both males and females, based
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on the national average age at menopause (51 years) to report whether participants
were older or younger than 51 years [104].
2.3.3 Statistical Analysis

We used a Chi-squared test to characterize the distribution of categorical

variables at diagnosis between males and females. Using Cox Proportional Hazard

Ratio models, we investigated survival, where the censored variable was death from
other causes or alive at last follow-up. All variables included in the chi-squared

analysis were evaluated in the baseline models. Baseline models included one

variable of interest and were adjusted for sex (for the overall population) and age.
Multivariable hazard ratios were adjusted for sex (for the overall population) and

age, and all other variables significant (p≤0.05) in the baseline model calculations. In
the multivariable analyses, Breslow thickness and age were used as continuous

variables. The Akaike Information Criterion (AIC) was used to determine the best
model fit. Kaplan-Meier curves were generated to graphically represent the

differences in survival between the sexes, and test the differences via the log-rank

test. Because Breslow thickness was not normally distributed, we utilized the MannWhitney-Wilcoxon test to compare distributions. To compare self-reported

menopause status with menopause status determined by the national average age at
menopause, we used diagnostic odds ratios. Two-sided tests were used for all

analyses and p≤0.05 was considered significant. All analyses were conducted in SAS
9.3 (SAS Institute, Cary, NC).
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2.4 Results:
2.4.1 Differences between men and women in the Connecticut population

Subjects were evenly distributed between the sexes, with 283 males (52.1%)

and 260 females (47.9%). We performed a chi-squared analysis to determine

differences between males and females in our population, including behavioral and
histopathological variables. Overall, the men in our study were older (p<0.01) and
more educated (p=0.01) (Table 2.1). Consistent with previous studies, we found

that males had an increased number of melanomas on their head and trunk, while

the majority of melanomas in females were on the extremities (p<0.01) (Table 2.1).
Fewer men had solar elastosis (p=0.04) (Table 2.1). Men also had slightly more

nodular melanomas and fewer melanomas that were classified as ‘other’ (p=0.01)
(Table 2.1). Men did not have thicker lesions than women (p=0.12); however,

because men are known to present with thicker lesions, we further investigated the
distribution of Breslow thickness by performing a Mann-Whitney-Wilcoxon test.

We found no significant difference, although men did tend to have thicker lesions

(p=0.08) (data not shown). Aside from anatomic site, solar elastosis, and histologic
subtype there were no significant differences in melanoma presentation between

men and women. Behavioral differences between men and women included a higher
number of men working outdoors (p<0.01), along with fewer men performing SSE

(p=0.02) and reporting skin awareness (p<0.01) (Table 2.1). Men also had

significantly more spouse/partner skin examinations than women (p<0.01) (Table

2.1).
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2.4.2 Deaths from melanoma at 5 and 15-year follow-up

In our population of melanoma cases, 96 participants died from melanoma. At

the five-year follow-up, 53 participants had died from melanoma, and at the 15-year

follow-up an additional 43 participants had died from melanoma. Of the total deaths
(n=96), 60.4% of deaths from melanoma were male participants, while 39.6%
percent were female participants. At the 5-year follow-up 54.7% (n=29) of

melanoma deaths were males, and 45.3% (n=24) were females. At the 15-year

follow-up, an additional 29 men had died from melanoma (67.4%) and only 14
women had died from melanoma (32.6%).

2.4.3 Factors contributing to 5-year survival in the Connecticut population (overall
and sex-stratified models)

Five-year survival results for this study were previously published by Berwick et

al (2005) [50]. Despite the different selection criteria for the two studies, the results
for the 5-year survival were quite similar, with the exception of anatomic site.

Anatomic site was not significant in our baseline model (p=0.38), and therefore, was
not included in our final multivariable model. However, when we included it in a
multivariable model for comparison with the previous study, anatomic site was
borderline significant (p=0.09).

For the model including all cases (referred to as overall population), Breslow

thickness was highly significant (adj+ HR 1.31, 95% CI=1.18-1.47, continuous per
mm) (Table 2.2). Mitoses were also a strong predictor of survival (adj+ HR 8.60,
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95% CI=1.75-42.26), as was solar elastosis (adj+ HR 0.49, 95% CI=0.25-0.94) and

skin awareness (adj+ HR 0.45, 95% CI=0.25-0.82) (Table 2.2).

In survival models stratified by sex, both males and females had an increased

hazard ratio for Breslow thickness (adj+ HR 1.31, 95% CI=1.14-1.51; adj+ HR 1.28,

95% CI=1.09-1.51, respectively) and a decreased hazard ratio for solar elastosis
(adj+ HR 0.40, 95% CI=0.17-0.95; adj+ HR 0.27, 95% CI=0.11-0.70, respectively)
(Table 2.2).

Regarding behavioral variables in our survival analyses, males also had a

reduced hazard ratio for intermittent sun exposure (adj^ HR 0.38, 95% CI=0.17-

0.82) (Table 2.2). Painful burns and skin awareness were not included in the

multivariable model, but were borderline significant in the baseline model (HR 0.50,
95% CI=0.24-1.04; HR 0.51, 95% CI=0.24-1.09, respectively). The only behavioral
variable associated with female survival was skin awareness (adj# HR 0.31, 95%

CI=0.13-0.76) (Table 2.2).

We also modeled survival stratified by sex using the variables that were included

in the overall population. To determine best model fit, we compared the AIC values
for each model. For females, the sex-specific model was the superior model as
demonstrated by lower AIC values (Table 2.2).

2.4.4 Factors contributing to 15-year survival in the Connecticut population (overall
and sex-stratified models)
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Similar to the 5-year follow-up data, Breslow thickness (adj+ HR 1.23, 95%

CI=1.13-1.34) and mitoses (adj+ HR 3.71, 95% CI=1.40-9.83) were associated with

survival in the overall 15-year follow-up models (Table 2.3). Skin awareness (adj+
HR 0.67, 95% CI=0.44-1.01) and solar elastosis (adj+ HR 0.64, 95% CI=0.40-1.01)

were borderline significant, but had less of an impact on survival than it did in the 5year survival models (Table 2.3).

In models stratified by sex, the only consistent predictor of survival was Breslow

thickness (males: adj^ HR 1.21, 95% CI=1.08-1.35; females: adj# HR 1.35, 95%

CI=1.13-1.60) (Table 2.3). Males had a significantly increased hazard ratio for
ulceration (adj^ HR 2.02, 95% CI=1.08-3.77). Intermittent sun exposure was

borderline significant (adj^ HR 0.63, 95% CI=0.36-1.09) (Table 2.3). Skin awareness

was not associated with survival in the baseline model for males (HR 0.83, 95%
CI=0.50-1.39), contrary to the 5-year baseline model. Females had a decreased
hazard ratio for solar elastosis (adj# HR 0.38, 95% CI=0.18-0.78) and skin

awareness (adj# HR 0.49, 95% CI=0.25-0.95) (Table 2.3). Using AIC values, we
showed that the sex-specific model was the best fit for both males and females
(Table 2.3).

2.4.5 Analyses stratified by Breslow thickness and sex

We generated Kaplan-Meier curves comparing survival between males and

females, which was significant (p=0.05) (Figure 2.1). We further compared survival
between men and women when stratifying by Breslow thickness. When comparing
survival curves of men and women with thin lesions (<1.00mm) and intermediate
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lesions (1.00-1.99mm) in Figure 2.2 (upper two lines and middles two lines in
graph, respectively), the curves are quite similar, and there is no significant
difference (p=0.45 and 0.60, respectively). However, there is a statistically

significant difference (p=0.03) in the survival curves of men and women diagnosed
with thick lesions (2.00+mm) (Figure 2.2, bottom two lines in graph).

Furthermore, men with intermediate lesions compared to men with thin lesions had
a higher hazard ratio in the baseline model (HR 5.97, 95% CI= 2.48-14.41) than

women with intermediate lesions compared to women with thin lesions (HR 3.54,
95% CI=1.59-7.91) (Table 2.3).

Given these findings, we hypothesized that a variable combining Breslow

thickness and sex (Breslow-sex; defined in methods) would be a better predictor of
survival than variables independently representing Breslow thickness and sex. The

AIC values were nearly identical with a value of 1094.6 for Breslow-sex, and 1094.8
for the model containing the individual Breslow thickness and sex variables.

Furthermore, when the multivariable model was calculated using categorical

variables for Breslow thickness, the Breslow-sex model was slightly preferred to the

model including Breslow thickness and sex separately (AIC=1079.5 and 1080.3,
respectively).

2.4.6 Menopause status and survival

Because age was significant only in the multivariable model for females (adj# HR

1.28, 95% CI=1.01-1.62), we investigated the effect of reported menopause status
on survival. We found that women who self-reported as post-menopausal at
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diagnosis had poorer survival than women who self-reported as pre-menopausal
(p<0.01) (data not shown).

To allow for comparison between men and women, we also categorized

participants based on national average age of menopause (51 years) [104]. We

compared the number of women who reported having gone through menopause
with the number of women age 51 and older, and found that average age at

menopause positively predicted menopause 87% of the time, and was specific 92%
of the time. Women older than 51 years had significantly worse survival than

women younger than 51 years of age (p=0.04), while there was no significant

difference in men (p=0.41) (Figure 2.3). Finally, women age 51 and older had

survival comparable to both categories of men, while women younger than 51 had
better survival (p=0.04) (Figure 2.3).

2.5 Discussion

Our findings suggest that there are different behavioral factors that contribute to

survival in males compared to females. Skin awareness was inversely associated

with mortality in females, but did not have an effect on survival in males. Similarly,

UV exposure including intermittent sun exposure, indoor tanning, and painful burns,
were inversely associated with mortality in males, but did not have an effect on

survival in females. However, solar elastosis, which is a pathological indicator of sun
exposure, was inversely associated with mortality in both males and females.

We also found that different histopathological variables contribute to survival in

males compared to females. Ulceration and mitoses were associated with an
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increased hazard ratio in males in the 15-year multivariable models, but did not
have an effect on survival in females. Breslow thickness was the only consistent
predictor of survival. However, the hazard ratio for Breslow thickness in males

decreased in the 15-year follow-up compared to the 5-year follow-up, while the

hazard ratio for females remained consistent. Interestingly, skin awareness was
borderline significant for males in the 5-year baseline model and represented a

protective effect, but this dissipated in the 15-year model. Taken together, these

results indicate that Breslow thickness and skin awareness are more predictive of

survival in females. Furthermore, processes independent of Breslow thickness may
influence progression of melanoma in males.

Additionally, we looked at a variety of factors that represent a hormonal

influence including age, number of children, number of pregnancies, ever use of

estrogen replacement, self-reported menopause status, and predicted menopause

status based on the average national age of menopause. We found that age was

significantly associated with an increased hazard ratio for females, but had no effect
on survival in males. Furthermore, women who were pre-menopausal when they

were diagnosed with melanoma had significantly better survival than post-

menopausal women. These results indicate that changes in estrogen-related

variables impact melanoma progression. Interestingly, this is approximately the age
at which the incidence rates also cross-over. Prior to age 50, women have a slightly
increased risk of developing melanoma. After age 50, risk among males rises
drastically and surpasses female risk [16].
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Overall, we found that factors contributing to survival in the 5-year follow-up

data were largely in agreement with factors contributing to survival in the 15-year

follow-up data. In general, the confidence intervals narrowed in the 15-year data,
representing increased power as expected. UV exposure variables that were

borderline significant or significant in the 5-year follow-up data for males did not

retain the same significance at the 15-year follow-up, indicating that UV exposures
have a larger impact on male survival closer to the time of diagnosis.

One limitation of our study is that we did not remove participants with lentigo

maligna melanoma, which is highly associated with solar elastosis and older age, in

order to retain power. It is possible that this biased our findings that solar elastosis
modified survival from melanoma; however, our findings are consistent with

previous reports regarding solar elastosis, including those published by Berwick et
al. (1996)[50]. We were unable to adjust for stage at diagnosis, which may have
limited our survival analyses of Breslow thickness and sex. However, we have

information on Breslow thickness, ulceration, and mitoses which are all of the

factors use to calculate stage; therefore, we had a proxy for stage in our analyses.

Furthermore, we do not have information about behavior or physiologic changes,
other than age, after diagnosis, which could also impact melanoma survival.

Our study also has multiple strengths. To our knowledge, we are the first to

report on survival regarding sex differences in melanoma with such extensive

follow-up information. Additionally, to our knowledge, we are the first to compare

the overall population to males and females separately, allowing the opportunity to
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identify information that is lost when simply adjusting for sex in survival models.
Furthermore, identification of the difference in the ability of certain factors to

modify survival, especially UV exposures, may help explain previously inconsistent
findings.

In summary, our study has identified that different factors contribute to survival

from melanoma in males compared to females. Results showing that age, self-

reported menopause status, and age-estimated menopause status affect survival in
women, but not men suggest that sex differences in survival may be attributable to
hormones. Additionally, men have poorer survival from thick lesions than women,

suggesting that there are biological differences in the progression, and perhaps the

initiation, of melanoma. Furthermore, skin awareness was borderline significant for
male survival in the 5-year models, suggesting that men who are aware of their skin
may present with thinner lesions. However, this trend dissipates in the 15-year
survival models, reinforcing that men’s melanomas may be inherently more

aggressive. It appears that there are biological differences in melanomas in males
compared to females, which may be due to inherent sex differences such as

hormones. Behaviors such as UV exposure and skin awareness may also interact
with inherent biological differences to drive the progression of melanoma.

While Breslow thickness was consistently significant for survival, we did identify

differences between males and females. As the best prognostic indicator for

melanoma, investigating Breslow thickness in a sex-stratified analysis may provide

more insight to the female survival advantage. Overall, this study further highlights
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the need for sex-stratified investigations to identify differences between melanomas
in males and females.
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2.6 Supplementary Data 1
Education status was categorized as completing college or not. Variables

including hair color, eye color, and tannability were combined to create a

“phenotype index” associated with melanoma risk as outlined by Kanetsky et al.

(2006) [105]. Nevi were counted and categorized as previously reported [99]. A
comorbidity index was created using eight of the ten categories proposed by

Charlson et al (1987)[106]. Our weighted co-morbidity score had a range of 0-11,

which was further categorized into three groups: none (0), mild (>0 and <3), and
severe (>3) [107].

Histopathology was reviewed by RLB. Breslow thickness was evaluated both

continuously and also categorized as thin (<1.00mm), intermediate (1.00-1.99mm),

and thick (2.00mm+), adhering to the AJCC staging guidelines for melanoma [12].
We also combined Breslow thickness and sex (Breslow-sex) into six categories

representing sex by thin, intermediate, and thick lesions. Histology was originally
recorded in multiple categories (superficial spreading, nodular, lentigo maligna,

acral, desmoplastic, neurotropic, other, and unclassified) and was re-categorized

into four groups: superficial spreading, nodular, lentigo maligna, and other. Mitoses
were reported as a continuous variable, and categorized as present or absent.
Vertical growth phase (VGP) was reported as no, yes, early, possible, and

indeterminate. We re-categorized early as yes, and possible/indeterminate as

missing. Tumor infiltrating lymphocytes (TILs) were reported as absent, non-brisk,
and brisk, and were re-categorized as absent or present. The anatomic site of the
melanoma lesion was reported in multiple categories (head/face/neck, upper
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shoulders/back, lower back, legs, arms, and other) and was collapsed into four

groups: head/neck, trunk, extremities, and other. Solar elastosis was originally
reported in multiple categories (none, slight, moderate, and marked), and was
collapsed to represent absent or present.

Reported number of sunburns was reported in multiple categories (0, 1-2, 3-4,

5-9, 10-14, 15-19, and 20+) and was collapsed into four groups: 0, 1-5, 6-10, and
>10, along with an ever/never categorization. Intermittent sun exposure was

created and categorized as high/low and was previously described; this variable
was also previously referred to as “lifetime sun exposure” and “recreational sun

exposure” [50,99,103]. Skin awareness was reported as multiple levels including
‘unaware’, ‘aware of skin cosmetically’, ‘aware of changes in skin’, ‘aware of

abnormalities in skin’, and ‘aware of other factors’. We re-categorized this variable
to represent ‘unaware’ or ‘aware’. Spouse examination was categorized as ‘no

examination’, ‘yes- spouse examined’, and ‘yes- other examined’. We re-categorized

this variable to represent never or ever examined by a spouse/partner/other.

Doctor examination was categorized as ‘yes’, ‘no’, ‘don’t know but assumed yes’, and
‘don’t know’. We combined ‘don’t know but assumed yes’ with ‘don’t know’, and

retained the categories ‘yes’ and ‘no’. A skin examination index variable was created.
If a participant’s skin had ever been examined by themselves, a spouse, or a doctor,

the skin examination index was recorded as ‘yes.’ If a participant’s skin had not been
examined by themselves, a spouse, or a doctor, the skin examination index was
recorded as ‘no.’ Females participating in the study were asked to report their

menopause status, which was reported in multiple categories to include medical
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considerations, pregnancies, and breastfeeding. This variable was collapsed into a

two-category variable including ‘pre-menopausal’ and ‘post-menopausal’. We also

created a variable, for both males and females, based on the national average age at
menopause (51 years) to report whether participants were older or younger than

51 years (17). Finally, we categorized the number of children each participant had
(0, 1, 2, 3+), which was originally reported as a continuous variable
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2.7 Tables and figures:
Table 2.1 Analysis of sex differences in Connecticut population
Males (n=283; 52.1%)
Female (n=260; 47.9%) p-value
n
%
n
%

Age
<30
30-39
40-49
50-59
60-69
≥70
Phenotype index
1
2
3
4
5
Completed college
No
Yes
5-year follow-up Status
Alive
Died from other causes
Died from melanoma
15-year follow-up Status
Alive
Died from other causes
Died from melanoma
Breslow thickness
Thin (<1.00mm)
Intermediate (1.00-1.99mm)
Thick (2.00+mm)
Anatomic site
Head/neck
Trunk/pelvis
Extremities
Other
Ulceration
No
Yes
Mitoses
No
Yes
Histology
Superficial spreading
Nodular
Lentigo maligna
Other
Vertical phase
No
Yes
TILs
Absent
Present
Missing
Solar elastosis

8
34
44
58
68
71

29
65
117
54
16
164
119
242
12
29
147
78
58
147
65
71
42
181
52
8
240
43
111
172
169
29
42
43
73
210
171
108
9
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2.8
12.0
15.6
20.5
24.0
25.1
10.3
23.1
41.6
19.2
5.7
58.0
42.1
85.5
4.2
10.3
51.9
27.6
20.5
51.9
23.0
35.1
14.8
64.0
18.4
2.8
84.8
15.2
39.2
60.8
59.7
10.3
14.8
15.2
25.8
74.2
61.3
38.7

15
42
61
55
40
47
18
48
92
65
22

178
82
226
10
24
172
50
38
156
55
49
35
83
135
7
224
36
107
153
180
22
41
17
80
180
170
85

5.8
16.2
23.5
21.2
15.4
18.1
7.4
19.6
37.6
26.5
9.0
68.5
31.5
86.9
3.9
9.2
66.2
19.2
14.6
60.0
21.2
18.9
13.5
31.9
51.9
2.7
86.2
13.9
41.2
58.9
69.2
8.5
15.8
6.5
30.8
69.2
66.7
33.3

<0.01

0.10
0.01

0.89
<0.01

0.12

<0.01
0.66
0.65

<0.01
0.21
0.20

No
Yes
Number of nevi
0
1 to 10
11 to 30
31 to 50
Greater than 51
Missing
Intermittent sun exposure
Low
High
Ever had a painful burn
Never
Ever
Number of painful sunburns
0
1 to 5
6 to 10
Greater than 10
Missing
Outdoor job
No
Yes
Indoor tanning
Never
Ever
Skin awareness
Unaware
Aware
Self-skin examination
No
Yes
Spouse-skin examination
No
Yes
Doctor-skin examination
No
Yes
Don't know
Skin examination index
No
Yes
Missing
Comorbidities
None
Mild
Severe
Number of children
0
1
2
3+
Estimated menopause (51 years)
Below 51 years
51 years and older

123
160
22
82
80
26
23
86

96
187
91
192
91
149
18
25
3
92
191
226
57
146
137
225
28
221
62
150
113
20
118
149
33

88
129
66
56
33
72
122
94
189
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43.5
56.5
9.4
35.2
34.3
11.2
9.9
33.9
66.1
32.2
67.8
32.2
52.7
6.4
8.8
32.5
67.5
79.9
20.1
51.6
48.4
90.1
9.9
78.1
21.9
53.0
39.9
7.1
44.2
55.8
31.1
45.6
23.3
19.8
11.7
25.4
43.1
33.2
66.8

91
169
16
90
80
24
14

101
159
86
174
86
130
16
25
201
59
197
63
81
179
217
43
230
30
153
90
17
123
120
82
110
68
49
39
75
97

125
135

35.0
65.0

0.04

7.1
40.2
35.7
10.7
6.3

0.50

38.9
61.2

0.23

33.1
66.9
33.5
50.6
6.2
9.7
77.3
22.7
75.8
24.2
31.2
68.9
83.5
16.5
88.5
11.5
58.9
34.6
6.5

0.82

0.96
<0.01
0.25
<0.01
0.02
<0.01

0.39

50.6
49.4

0.15

31.5
42.3
26.2

0.68

18.9
15.0
28.9
37.3
48.1
51.9

0.41
<0.01

Factor
Age (10years)
Sex
Completed college
Breslow thickness
Thin
Intermediate
Thick
Breslow thickness (continuous)
Ulceration
Mitoses
Vertical growth phase
Histologic subtype
Superficial spreading
Nodular
Lentigo maligna
Other
Solar elastosis
Indoor tanning
Intermittent sun exposure
Painful burn
Skin awareness
AIC values with covariates

Table 2. 5-year Survival Models: Overall, Males, and Females
Overall (n=543)
Males (n=283)
Baseline
Adjusted
Baseline
Adjusted
Adjusted
HR (95% CI)*
HR(95% CI)+
HR (95% CI)*
HR (95% CI)^
HR(95% CI)+
1.09(0.92-1.30) 1.04(0.85-1.27)
0.96 (0.75-1.22)
0.88(0.67-1.16)
0.8(0.60-1.05)
1.16(0.67-2.01) 0.99(0.55-1.80)
NA
NA
NA
0.56(0.29-1.07)
0.82 (0.38-1.76)
-

Baseline
HR (95% CI)*
1.24(0.97-1.59)
NA
0.22(0.05-0.97)

1.00(ref)
2.68(1.29-5.56)
0.67(0.25-1.80)
1.85(0.86-3.98)
0.28(0.15-0.52)
0.29(0.10-0.80)
0.63(0.36-1.09)
0.57(0.33-0.98)
0.34(0.19-0.62)

1.00(ref)
0.58(0.08-4.38)
0.53(0.14-1.91)
1.89(0.55-6.46)
0.19(0.07-0.48)
0.32(0.07-1.39)
0.70(0.31-1.60)
1.05(0.45-2.45)
0.23(0.10-0.55)

1.00(ref)
3.16(1.31-7.64)
11.74(5.59-24.64)
1.45(1.33-1.57)
3.44(1.91-6.21)
11.95(3.73-38.34)
6.90(2.15-22.14)

1.00 (ref)
5.91 (1.15-30.50)
39.98 (7.03-127.79)
1.31(1.18-1.47) 1.41 (1.28-1.55)
1.13(0.54-2.34)
4.87 (2.27-10.46)
8.60(1.75-42.26) 19.61 (2.67-144.28)
0.69(0.14-3.41) 10.49 (1.43-77.18)
1.00(ref)
0.79(0.35-1.80)
0.94(0.31-2.88)
0.99(0.43-2.27)
0.49(0.25-0.94)
0.41(0.14-1.17)
0.68(0.38-1.21)
0.45(0.25-0.82)

1.00 (ref)
5.08 (2.08-12.40)
0.81 (0.17-3.81)
2.17 (0.80-5.86)
0.36 (0.16-0.83)
0.30 (0.07-1.24)
0.44 (0.21-0.92)
0.50 (0.24-1.04)
0.51 (0.24-1.09)

Females (n=260)
Adjusted
Adjusted
HR(95% CI)#
HR(95% CI)+
1.24(0.93-1.66) 1.32(0.96-1.81)
NA
NA
0.37(0.08-1.63)
-

1.00(ref)
2.56(0.86-7.63)
5.53(2.12-14.42)
1.31(1.14-1.51)
1.31(1.14-1.51) 1.52(1.30-1.78) 1.28(1.09-1.51) 1.52(1.17-1.96)
1.69(0.69-4.14)
2.19(0.88-5.46)
1.98(0.77-5.08)
0.67(0.15-2.96)
15.3(0.68-346.18) 23.75(1.06-530.92) 7.99(1.88-34.04) 3.51(0.54-22.77) 4.01(0.62-25.58)
0.45(0.02-10.20)
0.29(0.01-6.76)
4.97(1.17-21.19) 1.31(0.20-8.76) 1.28(0.20-8.40)
1.00(ref)
1.40(0.48-4.06)
1.85(0.35-9.83)
1.57(0.57-4.30)
0.40(0.17-0.95)
0.38(0.17-0.82)
282.4

1.00(ref)
1.52(0.52-4.44)
2.43(0.43-13.84)
1.73(0.59-5.01)
0.60(0.25-1.45)
0.38(0.09-1.70)
0.29(0.13-0.66)
0.66(0.28-1.55)
278.8

Variables not significant (NS) in baseline models and therefore not included in adjusted models are listed as * Adjusted for sex (only in overall population) and age
+ Adjusted for all variables except those listed as - in overall population
^Adjusted for all variables except those listed as - in males
#Adjusted for all variables except those listed as - in females
NA=Not Applicable
Bold=Significant in adjusted models
Note: All variables included in the Chi-Square analysis (Table 2.1) were evaluated in the baseline models; significant variables are shown in the table
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0.27(0.11-0.70)
0.31(0.13-0.74)
225.8

1.00(ref)
0.14(0.02-1.26)
0.60(0.12-3.04)
0.44(0.08-2.37)
0.26(0.09-0.72)
0.36(0.08-1.61)
1.23(0.46-3.30)
0.27(0.11-0.69)
229.2

Factor
Age (10years)
Male sex
Completed college
Breslow thickness
Thin
Intermediate
Thick
Breslow thickness (cont.)
Ulceration
Mitoses
Vertical growth phase
Histologic subtype
Superficial spreading
Nodular
Lentigo maligna
Other
Solar elastosis
Indoor tanning
Intermittent sun exposure
Painful burn
Skin awareness
AIC values with covariates

Table 2.3 15-year Survival Models for the Overall Population, Males, and Females
Overall (n=543)
Males (n=283)
Baseline
Adjusted
Baseline
Adjusted
Adjusted
Baseline
HR (95% CI)*
HR(95% CI)+
HR (95% CI)*
HR(95% CI)^
HR(95% CI)+
HR (95% CI)*
1.17(1.02-1.33)
1.09(0.94-1.27)
1.97 (0.89-1.27)
0.94(0.77-1.14)
0.97(0.80-1.17)
1.31(1.07-1.59)
1.42(0.94-2.15)
1.12(0.73-1.73)
NA
NA
NA
0.74(0.74-1.16)
1.07 (0.63-1.80)
0.28(0.10-0.80)
1.00(ref)
4.41(2.46-7.92)
8.89(5.15-15.34)
1.34(1.26-1.43)
3.39(2.18-5.28)
7.47(3.76-14.86)
6.44(2.82-14.72)
1.00(ref)
2.83(1.60-5.02)
0.80(0.38-1.67)
3.18(1.92-5.27)
0.44(0.28-0.68)
0.40(0.21-0.76)
0.67(0.44-1.01)
0.81(0.54-1.24)
0.59(0.39-0.89)

1.00 (ref)
5.97 (2.48-14.41)
14.70 (6.49-33.26)
1.23(1.13-1.34) 1.31 (1.21-1.41)
1.41(0.86-2.32)
4.31 (2.47-7.55)
3.71(1.40-9.83) 8.12 (3.24-20.34)
1.16(0.37-3.68)
7.30 (2.28-23.35)
1.00(ref)
1.18(0.64-2.20)
1.28(0.58-2.81)
2.16(1.29-3.61)
0.64(0.40-1.01)
0.49(0.25-0.96)
0.67(0.44-1.01)

1.00 (ref)
4.10 (2.01-8.34)
0.84 (0.28-2.47)
3.74 (2.00-6.98)
0.56 (0.32-0.99)
0.42 (0.18-0.97)
0.59 (0.35-1.00)
0.87 (0.51-1.50)
0.83 (0.50-1.39)

1.21(1.08-1.35)
1.21(1.08-1.34)
2.02(1.08-3.77)
1.87(1.01-3.48)
3.62(0.94-13.93) 3.60(0.95-13.96)
1.13(0.21-6.02)
1.19(0.23-6.29)
1.00(ref)
1.66(0.76-3.59)
1.80(0.57-5.69)
2.85(1.51-5.37)
0.75(0.41-1.36)
0.45(0.19-1.08)
0.63(0.36-1.09)
578.05

1.00(ref)
1.74(0.81-3.75)
1.73(0.55-5.45)
2.82(1.48-5.36)
0.80(0.44-1.45)
0.43(0.18-1.04)
0.88(0.51-1.52)
580.50

1.00(ref)
3.54(1.59-7.91)
4.79(2.16-10.16)
1.53(1.33-1.76)
2.36(1.14-4.89)
6.61(2.34-18.66)
5.49(1.69-17.89)
1.00(ref)
1.58(0.55-4.58)
0.69(0.25-1.90)
2.84(1.15-7.01)
0.28(0.14-0.59)
0.41(0.14-1.17)
0.84(0.43-1.65)
0.75(0.39-1.45)
0.36(0.19-0.69)

Variables not significant (NS) in baseline models and therefore not included in adjusted models are listed as * Adjusted for sex (only in overall population) and age
+ Adjusted for all variables except those listed as - in overall population
^Adjusted for all variables except those listed as - in males
#Adjusted for all variables except those listed as - in females
NA=Not Applicable
Bold=Significant in adjusted models
Note: All variables included in the Chi-Square analysis (Table 2.1) were evaluated in the baseline models; significant variables are shown in the table
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Females (n=260)
Adjusted
HR(95% CI)#
1.28(1.01-1.62)
NA
0.39(0.13-1.13)

Adjusted
HR(95% CI)+
1.31(1.03-1.67)
NA
-

0.38(0.18-0.78)
0.49(0.25-0.95)
368.57

1.00(ref)
0.42(0.13-1.40)
0.82(0.26-2.63)
1.11(0.39-3.12)
0.41(0.19-0.90)
0.52(0.18-1.51)
0.44(0.23-0.88)
373.78

1.35(1.13-1.60)
0.75(0.31-1.83)
2.94(0.74-11.61)
1.49(0.31-7.10)

1.41(1.16-1.72)
0.87(0.33-2.33)
3.20(0.82-12.52)
1.34(0.29-6.33)

Figure 2.1 Survival by Sex
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Figure 2.2 Survival by Sex and Breslow Thickness
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Figure 2.3 Survival by Sex and Average Age of Menopause
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CHAPTER THREE:
BEHAVIOR AND BRESLOW THICKNESS: A SEX-STRATIFIED POPULATIONBASED STUDY OF MELANOMA

50

3.1 Abstract:
Background: Men have poorer survival from melanoma than women, perhaps in

part due to having thicker lesions at diagnosis. We sought to determine different
behavioral factors that contribute to Breslow thickness in males compared to
females

Methods: Multivariable linear regressions of log-transformed Breslow thickness

were performed using cases from a population-based case-control study of

melanoma patients (males n=283, females n=260). We modeled Breslow thickness
for all of the cases, as well as stratified by sex.

Results: In females, we found that UV exposures and skin awareness were

associated with decreased Breslow thickness. The association of UV exposure with
Breslow thickness in females remained significant in baseline models for women

who were unaware of their skin. In males, we did not identify any behavioral factors
that associated with Breslow thickness. Histopathological variables associated with

Breslow thickness were consistent across sexes. Skin awareness was not associated
with Breslow thickness in males; however, other variables that are associated with
skin awareness such as college education, indoor tanning, and painful burns were
comparable across males and females.

Conclusions: Skin awareness, while comparable in males and females, does not

contribute to Breslow thickness in males. UV exposures also modify Breslow
thickness in females, which is not due to its correlation with skin awareness.
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Impact: These findings suggest that thicker lesions at diagnosis cannot be

attributable to skin awareness in men. UV exposure association with Breslow

thickness in females but not males may explain previous inconsistencies in UV

exposure and melanoma survival. Future studies investigating UV exposure should
control for confounding by skin awareness.
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3.2 Introduction:
Melanoma is the most deadly form of skin cancer, and a female survival

advantage has been observed for decades [2,27,30,108]. There are multiple theories
regarding the female survival advantage including sex differences in behavioral
factors such as skin awareness, skin self-examination (SSE), and UV exposures

[100,102]. Others speculate that the female survival advantage is related to

hormonal differences between males and females, and the impact of sex steroid
hormones on both the immune system and reactive oxygen species [39,102].

Interestingly, there are differences in the presentation of melanoma between

males and females [20,21,109,110]. Men are more likely to develop melanomas on
their trunks, whereas females are more likely to develop melanomas on their
extremities [20,21,109,110]. Men are also more likely to develop nodular

melanomas, which are the most aggressive histopathological subtype, whereas
females are more likely to develop superficial spreading melanomas (SSM)

[20,21,109,110]. Finally, males are more likely to have a thicker lesion at diagnosis,
as measured by Breslow thickness in millimeters (mm), and an increased rate of

growth compared to females, suggesting that male melanomas are more aggressive
and develop differently [20,21,25,109,110]..

Breslow thickness is the depth of a melanoma lesion from the granular layer of

the skin to the deepest point, and is used in the current AJCC staging guidelines [12].
Importantly, Breslow thickness is the strongest and most consistent prognostic

indicator for melanoma. That is, as Breslow thickness increases, the survival rate
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decreases—a lesion <1mm has a 95-100% survival rate, a lesion 1.00-2.00mm has a

80-96% survival rate, a lesion 2.01-4.00mm has a 60-75% survival rate, and a lesion
>4.01mm has a 37-50% survival rate [16].

In our previous study of melanoma patients ascertained from the Connecticut

Tumor Registry, we found that males with thick lesions (>2.00mm) have poorer

survival than women with thick lesions (p=0.03) [111]. Additionally, we found that

the hazard ratio for Breslow thickness decreased in males from the 5-year follow-up

to the 15-year follow-up. That is, Breslow thickness at diagnosis was more

predictive of survival at the 5-year follow-up than the 15-year follow-up. However,
the 5-year and 15-year hazard ratios for Breslow thickness at diagnosis remained
consistent in females, indicating that Breslow thickness is a stronger long-term

predictor of survival in females compared to males [111]. Since Breslow thickness is

the best prognostic indicator for melanoma, and we previously observed differences
in Breslow thickness between males and females, sex-stratification of analyses

investigating Breslow thickness may provide more insights to the female survival

advantage. Therefore, we sought to determine the behavioral and biological factors
that contribute to Breslow thickness in males compared to females using the same
cohort of melanoma patients.
3.3 Methods

3.3.1 Subjects

This population has been described previously [99,111]. Briefly, 650 non-

Hispanic whites with cutaneous invasive melanoma were ascertained via the
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Connecticut Tumor Registry from January 15, 1987 to May 15, 1989. We removed

107 participants with missing information from our analysis, so that 543 individuals
make up the analysis dataset [111].
3.3.2 Statistical analysis

We used several summary variables (listed in Table 3.1) that were described

previously [111]. Most relevant to our findings, we used self-reported data to

determine skin awareness. To evaluate skin awareness, participants were asked,

“Prior to your biopsy, did you ever think about your skin, how it looked or whether
there were any changes; whether there were any abnormal marks?” Answers
included ‘No’, ‘Cosmetic changes’, ‘Abnormalities’, and ‘Other’. We created a

dichotomous variable representing aware/unaware, where any reported awareness
was considered aware, and the answer ‘No’ was considered unaware.

Chi-squared contingency tables were used to investigate differences between

males and females in the population. Because Breslow thickness is not normally

distributed, we used the nonparametric Mann Whitney Wilcoxon test to compare

average Breslow thickness between males and females. Using linear regression, we
built models for Breslow thickness for all of the cases (referred to as overall

population), along with males and females separately. In the linear regressions, we
used log-transformed Breslow thickness as the outcome to correct for the non-

normal distribution of Breslow thickness. Baseline models included a variable of
interest and were adjusted for sex (for the overall population) and age.

Multivariable odds ratios included all variables significant in the baseline model
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(p≤0.05), and were adjusted for sex (for the overall population) and age. Output

from the linear regressions modeling Breslow thickness was exponentiated, so odds
ratios represent increases in Breslow thickness per 1mm. We also performed chisquared contingency analyses to investigate associations of skin awareness with
Breslow thickness, college education, indoor tanning, and ‘ever had a painful

sunburn’ (referred to as painful burns). Each analysis was performed using two-

sided test and p≤0.05 was considered significant. All analyses were performed in

SAS 9.3 (SAS Institute, Cary, N.C.).
3.4 Results

3.4.1 Differences between men and women with melanoma in Connecticut

As previously reported, subjects were evenly distributed between the sexes,

with 283 males (52.1%) and 260 females (47.9%) [111]. Significant differences

were: men in our study were older (p<0.01) and more educated (p=0.01), had an

increased number of melanomas on their head and trunk (p<0.01), and were less

likely to have solar elastosis (Table 3.1). We performed a Mann Whitney Wilcoxon
test to further investigate the distribution of Breslow thickness. There was a nonsignificant trend towards men having thicker lesions (p=0.08) (data not shown).

Fewer men had performed SSE (p=0.02), and they were less likely to report skin
awareness (p<0.01), yet were more likely to have skin examinations from a
spouse/partner compared to women (p<0.01) (Table 3.1).
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3.4.2 Breslow thickness models including other histopathological factors

For the overall population and both of the sex-stratified analyses, ulceration,

mitoses, vertical growth phase, and histological subtype were significantly

associated with increased Breslow thickness (Table 3.2). Sex-related differences

included males having an increased Breslow thickness when mitoses were present

compared to females (adj. OR 5.19, 95% CI=3.20-8.42 vs. adj. OR 3.18, 95% CI=2.025.01). Further, females had a slightly increased Breslow thickness for nodular

melanomas (adj. OR 4.69, 95% CI=2.62-8.42) compared to males (adj. OR 3.80, 95%
CI=2.14-6.73).

Regarding behavioral factors, skin awareness and indoor tanning were

associated with Breslow thickness in the baseline model for the overall population.

Similarly, skin awareness, indoor tanning, and painful sunburns were associated

with Breslow thickness in the baseline model for females. However, none of these
behavioral factors were significant in the baseline model for males, and therefore

were not included in the adjusted model. In the adjusted model, skin awareness was
the only behavioral variable that remained significant for the overall population (OR
0.67, 95% CI=0.47-0.97) and females (OR 0.72, 95% CI=0.52-1.00), but was not

protective in males (Table 3.2). Additionally, indoor tanning and painful sunburns
were borderline significant in the female model (OR 0.72, 95% CI=0.52-1.02; OR
0.77, 95% CI=0.56-1.07, respectively) (Table 3.2).
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3.4.3 Breslow thickness models excluding other histopathological factors

Because collinearity between Breslow thickness and other histopathological

factors occurs and is difficult to correct for, we also modeled Breslow thickness
using only behavioral variables. This was only done for the overall and female

models given that we did not find any behavioral factors associated with Breslow
thickness in the baseline model for males (Table 3.2).

For the overall population, age was significantly associated with increased

Breslow thickness (OR 1.14, 95% CI=1.02-1.27) (Table 3.2). Skin awareness was

significantly associated with a decreased Breslow thickness (OR 0.67, 95% CI=0.470.97), along with indoor tanning, which was borderline significant (OR 0.66, 95%
CI=0.43-1.01) (Table 3.2).

In the analysis stratified by females, painful sunburns and skin awareness were

significantly associated with decreased Breslow thickness (OR 0.61, 95% CI=0.37-

1.00; OR 0.56, 95% CI=0.34-0.94, respectively) (Table 3.2). Additionally, age and
indoor tanning were borderline significant (OR 1.11, 95% CI=0.96-1.29; OR 0.61,
95% CI=0.35-1.07, respectively) (Table 3.2).

3.4.4 Factors associated with skin awareness

Skin awareness was a self-reported variable, and could have differing results in

males compared to females because of potential recall bias and variance in

interpretation of the question. To account for these concerns, we performed a chi58

squared contingency analysis to compare factors that could be a proxy for skin
awareness in the overall population, males, and females (Table 3.3). A higher

percentage of participants who were college educated, indoor tanned, and painful

sunburns also reported being aware of their skin for the overall population, as well
as males, and females, indicating that the self-reported variable was comparable
across the sex-stratification (Table 3.3). Furthermore, a higher percentage of

participants with thin lesions reported being aware of their skin in the overall

population and in females (62.4% and 75.0%, respectively) (Table 3.3). However,
in the male stratification, a higher percentage of participants with intermediate

lesions reported being aware of their skin (55.4%), while only 49% of participants
with thin lesions reported being aware of their skin (Table 3.3). Taken together,

these results show that males with comparable skin awareness are diagnosed with

thicker lesions, suggesting that men have more aggressive melanomas than women.

3.4.5 Factors associated with Breslow thickness in participants who are unaware of
their skin

To remove any confounding from correlations between skin awareness and UV

exposures, we investigated the baseline linear regression model of Breslow

thickness for participants who reported being unaware of their skin. In the overall

population, 227 participants (41.8%) reported being unaware of their skin (data not
shown). For the sex-stratified analyses, there were 146 (51.6%) male participants
and 81 (31.2%) female participants (data not shown). In the baseline model,

ulceration, mitoses, vertical growth phase, and histological subtype remained
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significantly associated (p<0.01) with increased Breslow thickness for the overall
population and both sex-stratified analyses (data not shown). Painful sunburns

were not significant in the overall population or in males; however, it remained

inversely associated with Breslow thickness in females (p=0.04) (data not shown).
Indoor tanning was not significant in any of the models (data not shown).
3.5 Discussion

Our findings suggest that the histopathological factors that contribute to or are
collinear with Breslow thickness are the same between males and females.

However, we found that behavioral factors, such as skin awareness, indoor tanning,
and painful sunburns are inversely associated with Breslow thickness in females.
Conversely, we did not find any association with behavioral factors and Breslow
thickness in males.

Although it is difficult to assess UV exposures due to potential confounding with

skin awareness, our findings suggest that UV exposure association with Breslow
thickness in females is a real effect. When we investigated UV exposures and

Breslow thickness in participants who reported being unaware of their skin, painful
sunburns were inversely associated with Breslow thickness in females, but not
males or the overall population. We found that indoor tanning was no longer

associated with Breslow thickness, but this may be due to the small number of

females who reported being unaware of their skin and had indoor tanned (n=13,
16.0%).
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Our previous study investigating melanoma survival revealed that UV exposure

was inversely associated with mortality in males, but had no association in females

[111]. Conversely, UV exposure was inversely associated with Breslow thickness in

females, but had no association in males. Taken together, these findings suggest that
UV exposure impacts male survival independent of Breslow thickness. We can also

conclude that UV exposure was not significant in the female survival model because
its effect was encompassed by Breslow thickness. Since anatomic site distributions
are different in men and women, and UV exposure also varies by anatomic site, it
could also play a complex role in melanoma sex differences.

One limitation of our study is that we did not remove participants with lentigo

maligna melanoma (LMM) (n=83) to retain power. LMM is highly associated with

solar elastosis, which is a histopathological marker of sun exposure that increases
with age. Inclusion of participants with LMM could have affected our ability to

accurately assess the impact of UV exposures on Breslow thickness. However, this is
unlikely as solar elastosis was not significant in any of the models including

histopathological factors. We were also limited in our ability to confirm the finding

that indoor tanning was inversely associated with Breslow thickness in participants
who were unaware of their skin.

Our study has multiple strengths. To our knowledge, this is the first study to

investigate factors that contribute to Breslow thickness, especially in a sex-stratified
manner. We are also the only study to consider the potential confounding between
skin awareness and other variables that can be considered a proxy for skin
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awareness, such as indoor tanning. Finally, our careful examination of UV exposure
and Breslow thickness in a sex-stratified approach provides explanation for

previously inconsistent results regarding UV exposure and Breslow thickness.
In summary, our study has shown the importance of behavioral factors in

relation to Breslow thickness in females. Furthermore, we did not find any

behavioral factors that contribute to Breslow thickness in males. Because UV

exposures are inversely associated with mortality in males, we can conclude that UV
exposures impact melanoma progression differently in males compared to females.
Future studies distinguishing the role of sex steroid hormones in response to UV

exposure and melanoma progression are merited. Additionally, we found that UV

exposures such as painful sunburns and indoor tanning were associated with skin

awareness suggesting that population-based studies investigating UV exposure and
melanoma should control for skin awareness as a confounder. Finally, our findings
highlight the importance of sex-stratified analyses in melanoma research.
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3.6 Tables:
Table 3.1 Analysis of sex differences in Connecticut population
Adapted from Lilyquist et al.*[111]

Age
<30
30-39
40-49
50-59
60-69
≥70
Completed college
No
Yes
15-year follow-up Status
Alive
Died from other causes
Died from melanoma
Breslow thickness
Thin (<1.00mm)
Intermediate (1.00-1.99mm)
Thick (2.00+mm)
Anatomic site
Head/neck
Trunk/pelvis
Extremities
Other
Histology
Superficial spreading
Nodular
Lentigo maligna
Other
Solar elastosis
No
Yes
Outdoor job
No
Yes
Skin awareness
Unaware
Aware
Self-skin examination
No
Yes
Spouse-skin examination
No
Yes
Average age at menopause (51 years)
Below 51 years
51 years and older

Males (n=283; 52.1%) Female (n=260; 47.9%) p-value
n
%
n
%
8
34
44
58
68
71

164
119
147
78
58
147
65
71
42
181
52
8
169
29
42
43
123
160
92
191
146
137
225
28
221
62
94
189

2.8
12.0
15.6
20.5
24.0
25.1
58.0
42.1
51.9
27.6
20.5
51.9
23.0
35.1
14.8
64.0
18.4
2.8
59.7
10.3
14.8
15.2
43.5
56.5
32.5
67.5
51.6
48.4
90.1
9.9
78.1
21.9
33.2
66.8

15
42
61
55
40
47

178
82
172
50
38
156
55
49
35
83
135
7
180
22
41
17
91
169
201
59
81
179
217
43
230
30
125
135

5.8
16.2
23.5
21.2
15.4
18.1
68.5
31.5
66.2
19.2
14.6
60.0
21.2
18.9
13.5
31.9
51.9
2.7
69.2
8.5
15.8
6.5
35.0
65.0
77.3
22.7
31.2
68.9
83.5
16.5
88.5
11.5
48.1
51.9

<0.01
0.01

<0.01

0.12

<0.01

<0.01
0.04
<0.01
<0.01
0.02
<0.01
<0.01

*Phenotype index, 5-year follow-up status, ulceration, mitoses, number of nevi, intermittent sun
exposure, ever had a painful burn, number of painful sunburns, indoor tanning, doctor skinexamination, skin exam index, comorbidities, and number of children were previously evaluated and
reported as not significant between males and females in this population
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Factor
Age (10years)
Sex
Indoor tanning
Ever had a painful burn
Skin awareness
Solar elastosis
Ulceration
Mitoses
Vertical growth phase
TILs
Histologic subtype
Superficial spreading
Nodular
Lentigo maligna
Other

Table 3.2 Breslow thickness models for the overall population, males, and females
Overall (n=543)
Males (n=283)
Females (n=260)
Adjusted with
Adjusted
Adjusted with
Adjusted with
Baseline*
Histolpath.^
Behavior Only^
Baseline*
Histolpath.^
Baseline*
Histolpath.^
OR (95% CI)
OR(95% CI)
OR(95% CI)
OR (95% CI)
OR(95% CI)
OR (95% CI)
OR(95% CI)
1.17(1.04-1.30)
1.05(0.97-1.14) 1.14(1.02-1.27) 1.12(0.95-1.32)
1.02(0.91-1.16)
1.21(1.05-1.41) 1.08(0.97-1.21)
NA
1.26(0.89-1.79)
1.03(0.82-1.30) 1.16(0.81-1.65)
NA
NA
NA
0.62(0.41-0.95)
0.94(0.72-1.24) 0.66(0.43-1.01) 0.71(0.38-1.35)
0.56(0.32-0.98) 0.72(0.52-1.02)
0.81(0.56-1.17)
1.15(0.67-1.99)
0.550.34-0.92)
0.77(0.56-1.07)
0.65(0.45-0.93)
0.81(0.64-1.02) 0.67(0.47-0.97) 0.78(0.47-1.30)
0.51(0.31-0.85) 0.72(0.52-1.00)
0.48(0.33-0.71)
0.86(0.66-1.11)
0.50(0.29-0.88)
0.84(0.58-1.23)
0.47(0.28-0.78) 0.87(0.62-1.23)
13.83(8.86-21.58)
3.38(2.41-4.74)
13.66(7.16-26.03)
3.18(1.97-5.14) 13.94(7.57-25.70) 3.66(2.26-5.91)
17.23(13.25-22.41
4.20(3.01-5.86)
22.21(15.21-32.43) 5.19(3.20-8.42) 13.16(9.16-18.91) 3.18(2.02-5.01)
19.22(14.28-25.88) 3.86(2.66-5.59)
26.17(16.83-40.68) 4.68(2.70-8.09) 14.14(9.50-21.04) 3.42(2.08-5.62)
3.70(2.60-5.25)
0.94(0.72-1.22)
3.91(2.35-6.50)
0.95(0.65-1.39)
3.49(2.16-5.66) 0.89(0.62-1.28)
1.00(ref)
1.00(ref)
1.00(ref)
1.00(ref)
1.00(ref)
1.00(ref)
16.36(9.88-29.44)
4.40(2.93-6.60)
16.10(7.39-35.07)
3.80(2.14-6.73) 19.72(9.36-41.51) 4.69(2.62-8.42)
0.61(0.38-0.98)
0.95(0.67-1.34)
0.53(0.27-1.04)
1.01(0.60-1.70)
0.76(0.41-1.39) 0.84(0.54-1.33)
4.43(2.65-7.42)
1.83(1.26-2.65)
3.41(1.6-6.61)
1.45(0.90-2.35)
9.33(4.05-21.51) 2.83(1.51-5.29)

Variables not significant (NS) in baseline models and therefore not included in adjusted models are listed as * Adjusted for sex (only in overall population) and age
^Adjusted for all variables except those listed as – in adjusted models
NA=Not Applicable
Bold=Significant in adjusted models
Note: All variables included in the Chi-Square analysis (Table 3.1) were evaluated in the baseline models; significant variables are shown in the table
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Adjusted
Behavior Only^
OR(95% CI)
1.11(0.96-1.29)
NA
0.61(0.35-1.07)
0.61(0.37-1.00)
0.56(0.34-0.94)

-

Factor
Breslow thickness
Thin (<1.0mm)
Intermediate (1.00-1.99mm)
Thick (2.00+mm)
p-value
Completed college
No
Yes
p-value
Indoor tanning
Never
Ever
p-value
Painful burn
Never
Ever
p-value

Table 3.3 Chi-squared: Associations with Skin Awareness
Overall n=543
Males n=283
Females n=260
Unaware n (%) Aware n (%) Unaware n (%) Aware n (%) Unaware n (%) Aware n (%)
114 (37.6)
51 (42.5)
62 (51.7)
148 (46.4)
171 (53.6)
192 (45.4)
35 (29.2)
93 (52.5)
134 (36.6)

189 (62.4)
69 (57.5)
58 (48.3)
0.03

75 ( 51.0)
29 (44.6)
42 (59.2)

63 (32.5)
131 (67.5)
<0.01

163 (47.7)
64 (31.8)

84 (47.5)
232 (63.4)
<0.01

58 (63.7)
88 (45.8)

231 (54.6)
85 (70.8)
<0.01
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124 (54.9)
22 (38.6)

72 (49.0)
36 (55.4)
29 (40.9)
0.23

39 (25.0)
22 (40.0)
20 (40.8)

102 (45.1)
35 (61.4)
0.03

68 (34.5)
13 (20.6)

179 (52.3)
137 (68.2)
<0.01

65 (36.5)
16 (19.5)

33 (36.3)
104 (54.2)
<0.01

35 (40.7)
46 (26.4)

117 (75.0)
33 (60.0)
29 (59.2)
0.03
113 (63.5)
66 (80.5)
<0.01
129 (65.5)
50 (79.4)
0.03
51 (59.3)
128 (73.6)
0.02

CHAPTER FOUR:
DNA REPAIR VARIANTS, BRESLOW THICKNESS, AND UV EXPOSURES IN A SEXSTRATIFIED ANALYSIS OF MELANOMA
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4.1 Abstract:
Background: SNPs in DNA repair genes have previously been associated with

melanoma risk and survival, but not Breslow thickness. DNA repair SNPS have also

been shown to interact with UV exposures, which vary between males and females.
Methods: Using cases from the Minnesota Skin Health study, we performed

multiple logistic regressions stratified by sex to investigate SNP associations with
Breslow thickness. We also investigated SNP interactions with UV exposures that
modify Breslow thickness.

Results: We identified 3 SNPs associated with Breslow thickness in males, and 7

SNPs associated with Breslow thickness in females. Only 1 SNP was significant in
both sexes. We identified 10 SNPs that interacted with UV exposures to modify
Breslow thickness in males, and 13 SNPs in females. None of the SNPs in the

interaction analysis overlapped between sexes. SNPs identified in males were

largely associated with increased Breslow thickness, and SNPs identified in females

were largely associated with decreased Breslow thickness. The SNP analyses for all
of the cases was not representative of the results in the sex-stratified analyses.

Conclusions: Biological differences in DNA repair between the sexes may help

explain the female survival advantage. Varying interactions with DNA repair SNPs

and UV exposures between the sexes may help explain previous inconsistencies in
UV exposure association with Breslow thickness and survival.
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4.2 Introduction:
Ultraviolet (UV) radiation is the only well-established environmental risk factor

for melanoma. It is thought that UV exposure causes melanoma by inducing DNA
damage via reactive oxygen species, and formation of bulky adducts such as

cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts [112]. The DNA

damage induced by UV exposure is generally repaired by two major DNA repair

mechanisms: base excision repair (BER) and nucleotide excision repair (NER) [112].
NER generally repairs CPDs and 6-4 photoproducts, while BER generally repairs

oxidative damage; however, there is overlap between the two pathways [112,113].

Interestingly, there are inter-individual variations in the efficiency of DNA repair

capacity that have been associated with single nucleotide polymorphisms (SNPs) in
healthy individuals [73]. Therefore, investigating DNA repair SNPs in relation to

diseases, especially cancers, may be important [73]. SNPs in multiple DNA repair

genes and pathways have previously been associated with melanoma risk [89,94–

96,114–117]. Furthermore, the effect of indoor tanning on melanoma risk appears
to be modified by variants in DNA repair [95].

UV exposure has also been associated with melanoma survival, although

inconsistently. In 2005, Berwick et al. reported a protective effect of UV exposure on
melanoma survival with 5 years of follow-up information [50]. Using the same

dataset, Lilyquist et al. (in preparation) found that UV exposure had a protective
effect at 5-year follow-up, particularly in males, which dissipated at the 15-year

follow-up [111]. In a validation study using 7-year follow-up information in a much
larger population, Berwick et al. (2014) found that there was a weak protective
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effect of UV exposure on melanoma survival [53]. Rosso et al. also reported

increased survival for participants with intermittent sun exposure prior to diagnosis
[118]. In contrast, Fortes et al. associated high UVB exposure with an increased
mortality from melanoma located on the lower extremities, but found no

associations with other anatomic sites [119]. Multiple SNPs in DNA repair genes
have been associated with melanoma survival [71,120–122]. Therefore, it is
possible that gene-environment interactions could explain the reported
inconsistencies between UV exposure and survival.

UV exposure has also been associated with Breslow thickness—the best

prognostic indicator for melanoma [53,123]. In 2013, Gandini and colleagues

reported that taking sunny holidays was associated with thinner lesions in women,

but not in males [123]. However, no studies have reported on associations between

Breslow thickness and DNA repair SNPs to date.

Of note, there is a female survival advantage in melanoma, suggesting that there

are biological differences in the progression of melanoma between males and
females [26,27,31]. Previous studies investigating UV exposure in relation to

melanoma survival and Breslow thickness have shown that UV exposure affects
melanoma survival differently in males and females [111,123]. Furthermore,

previous studies investigating DNA repair capacity have suggested differences

between males and females [73,74]. Therefore, investigating associations between
Breslow thickness and DNA repair SNPs in a sex-stratified manner may provide

insight to the progression of melanoma in males compared to females. For that
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reason, we sought to determine whether DNA repair SNPs are associated with

Breslow thickness. We hypothesized that DNA repair SNPs differentially associate
with Breslow thickness in males compared to females.
4.3 Methods:

4.3.1 Study Population

The Minnesota Skin Health Study has been previously described [124]. Briefly,

cases were ascertained through the Minnesota State Cancer Registry. Patients aged

25 to 59 who were diagnosed with invasive cutaneous melanoma between 2004 and
2007 were enrolled. Controls were randomly selected from the state drivers’ license
list and frequency-matched based on age and sex. The State Cancer Registry and the

University of Minnesota Institutional Review Boards approved the protocol for this
study. Of the eligible participants, 1167 cases and 1101 controls completed a selfadministered questionnaire designed to evaluate UV exposures, along with a

telephone interview. Histopathology variables were obtained from the diagnostic
pathology report. Of these subjects, 1755 (77.4%) submitted DNA samples for

genotyping and 9 participants were removed for missing consents, leaving 1746
(929 cases, 817 controls) participants for genotyping.
4.3.2 Selection of SNPs

SNP selection for this study has been previously described [95]. Briefly, 154

SNPs from 28 DNA repair genes from multiple DNA repair pathways were chosen
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based on 1) reported function in the literature and 2) tagging coverage using
Haploview 4.1.

4.3.3 Genotyping platform

The genotyping platform for this study has been previously described [95].

Briefly, buccal cell DNA was collected using SCOPE® mouthwash, extracted using

Qiagen® kits, quantitated, and genotyped on the Illumina BeadExpress GoldenGate®
platform by the University of Utah Genotyping Core. All 1746 participants that
submitted DNA samples were genotyped.

4.3.4 Quality control

From the genotyped population (n=1746), we removed 46 non-white

participants and 7 participants with missing phenotypic index [95]. Using a 95% call
rate as the cutoff, an additional 34 participants and 8 SNPs were removed from the

analysis [95]. We also removed 7 monomorphic SNPs and 47 SNPs that had a minor
allele frequency (MAF) less than 0.05 [95]. This resulted in a study consisting of

1659 participants (893 cases, 766 controls) and 92 SNPs in 20 DNA repair genes
[95]. Finally, 4 SNPs (rs4253114, rs10764889, rs7075505, and rs574831) in the
study were significant (p<0.01) for Hardy Weinberg Equilibrium (HWE) as

described previously [95]. These SNPs were not removed from the analysis, but

associations with these SNPs discovered in our study are noted and interpreted with
caution.
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For our analysis, we removed all participants with a missing Breslow thickness,

including all of the controls, and missing age or sunburn information, resulting in

723 melanoma cases. Once again, we removed participants (n=0) and SNPs (n=1)

with a call rate less than 95%, for a total of 723 participants and 91 SNPs in 20 DNA
repair genes. We also removed any SNPs (n=1) and participants (n=0) with a call

rate less then 95% in the sex-stratified analyses, which resulted in one SNP being

removed from the male analysis. The final genotyping call rate, for all of the cases
(referred to as overall population) and both of the sex-stratified analyses, was

99.8%. Participants with missing Breslow thickness were removed using SAS 9.3
(SAS Institute, Cary, NC), and all other steps in the quality control process were
performed using PLINK 1.07 [125].
4.3.5 Statistical analysis

All analyses were performed using two-sided tests and p≤0.05 was considered

significant.

We performed a chi-squared contingency analysis to compare differences

between men and women in the population using SAS 9.3 (SAS Institute, Cary, NC).
Multiple logistic regression analyses in PLINK 1.07 were performed to

investigate the association of each SNP with Breslow thickness using an additive

genotype model [125]. Breslow thickness was split into two categories: thin (less

than 1mm) and thick (greater than 1mm). We modeled Breslow thickness for all of
the overall population, along with males and females separately. Odds ratios,
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confidences intervals, and p-values were adjusted for age as a continuous variable

(in all models) and sex (in the models for the overall population). We evaluated all
associations for multiple comparisons using the False Discovery Rate.

We also assessed SNP interactions with UV exposures including indoor tanning

status and number of painful sunburns (childhood, adult, and total) in PLINK 1.07

[125]. For these analyses, we investigated multiplicative interactions using multiple
logistic regression that included the main effects and interaction term for the SNP
and the UV exposure of interest. The p-values for the interactions on the

multiplicative scale were calculated using Wald tests for the interaction term. The
interaction analyses were adjusted for sex (in the overall population) and age.
4.4 Results:

4.4.1 Differences between males and females in the Minnesota population

The Minnesota Skin Health Population had more females than males (61.4% and

38.6%, respectively) (Table 4.1). We first calculated differences between males and
females in the population using a chi-squared analysis. Males were older (p<0.01)
and more educated (p<0.01) (Table 4.1). Regarding tumor characteristics, males

had thicker lesions at diagnosis (p<0.01) and the majority of their melanomas on the
trunk while females had thinner lesions at diagnosis and the majority of their

melanomas on their extremities (p<0.01). Histological subtype was also distributed
differently among males and females, with males having more nodular melanomas
(p<0.01) (Table 4.1). Pertaining to behavioral factors, fewer males had indoor

tanned (p<0.01) and more males reported having greater than ten painful burns as a
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child, as an adult, and total number of lifetime sunburns (p=0.11, p<0.01, and

p=0.02, respectively) (referred to as childhood burns, adulthood burns, and lifetime
burns) (Table 4.1).

4.4.2 SNP associations with Breslow thickness in the overall population

In the overall population, we identified six SNPs that were associated with

Breslow thickness at diagnosis after adjustment for age and sex (p≤0.05) (Table
4.2). Four of the SNPs are located in NER genes: RFC1 (rs2066786, rs2066782),

ERCC4 (rs1800067), and ERCC6 (rs4253114) (Table 4.2). Both SNPs in RFC1 along

with the SNP in ERCC4 had a decreased odds ratio of a thick lesion (>1mm). The SNP
in ERCC6 was associated with an increased risk of having a thick lesion (Table 4.2).
Two of the SNPs (rs1574157 and rs12315756) were located in FBRSL1—a gene

previously associated with DNA repair (Table 4.2). rs12315756 was inversely

associated with Breslow thickness and rs1574157 was positively associated with
Breslow thickness (Table 4.2).

4.4.3 SNP associations with Breslow thickness in males

In males, there were three SNPs that were associated with an increased risk of

having a thick lesion after adjustment for age (p≤0.05) (Table 4.2). Two of the SNPs
are located in NER genes: ERCC5 (rs876430) and ERCC6 (rs4253114) (Table 4.2).

The remaining SNP was in another gene previously associated with DNA repair,
FBRSL1 (rs1574157) (Table 4.2).

4.4.4 SNP associations with Breslow thickness in females
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In females, seven SNPs were associated with Breslow thickness (Table 4.2).

PARP1 (rs1805414), in the BER pathway, was associated with decreased odds of
having a thick lesion (Table 4.2). We identified five SNPs in the NER pathway

(Table 4.2). Three of the SNPs (rs2066786, RFC1; rs1800067, ERCC4; rs7325708,
ERCC5) were inversely associated with Breslow thickness, and two of the SNPs

(rs4253114, ERCC6; rs4150355, ERCC5) were associated with increased Breslow
thickness (Table 4.2). There was also a SNP (rs12315756) in FBRSL1, which is

involved in transcription, that was inversely associated with Breslow thickness
(Table 4.2).

4.4.5 Comparison of SNP associations in the overall population, males, and females
There was not complete overlap between the SNP analyses for the overall

population compared to the sex-stratified analysis (Tables 4.2 and 4.3). In fact,
there was only one SNP, rs4253114 (ERCC6), that was significant in the overall

population and both stratified models (Tables 4.2 and 4.3). For the 3 SNPs that

were uniquely significant in the female analysis, the odds ratio was in the opposite
direction to the male population (Table 4.3). Likewise, for the SNP that was

uniquely significant in the male analysis, the odds ratio was in the opposite direction
to the female population (Table 4.3).

4.4.6 Interactions with DNA repair SNPs and UV exposures in the overall population
For the overall population, 13 SNPs interacted with different measures of UV

exposure; there were no interactions with SNPs and childhood burns (Table 4.4).
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The two SNPs that interacted with indoor tanning (rs4253126) and lifetime

burns (rs4253079) are both located in ERCC6 and are inversely associated with
Breslow thickness (OR 0.42, 95% CI=0.19-0.92; OR 0.27, 95% CI=0.11-0.66,

respectively) (Table 4.4). That is, someone with the minor allele for these two SNPs
who has ever indoor tanned and had greater than 10 lifetime painful burns has a

decreased risk of a lesion thicker than 1mm compared to someone who has either
the minor allele or has ever indoor tanned/had greater than 10 lifetime painful
burns.

Conversely, the 11 SNPs that interacted with adulthood burns were associated

with an increased Breslow thickness (Table 4.4). Interestingly, these 11 SNPs

spanned multiple DNA repair pathways including NER, BER, MGMT, and others

(Table 4.4). Furthermore, rs4253114 in ERCC6 was also associated with increased
Breslow thickness (as discussed above).

4.4.7 Interactions with DNA repair SNPs and UV exposures in males

In males, we found 1 SNP interacted with indoor tanning and 9 SNPs interacted

with adulthood burns to modify Breslow thickness (p≤0.05) (Table 4.5). There

were no SNPs that interacted with childhood burns or lifetime burns (Table 4.5).

Interestingly, all 10 SNPs identified in this analysis interacted with UV exposures to
increase Breslow thickness (Table 4.5). The SNPs were in genes involved in

multiple DNA repair pathways including NER, BER, MGMT, and other (Table 4.5). Of

note, five of the ten SNPs identified were in the MGMT gene/pathway (Table 4.5).
Additionally, one SNP in ERCC5 (rs4150355) that was associated with increased
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Breslow thickness in females (no interaction in females) also interacted with

adulthood burns to increase Breslow thickness in males (Table 4.3 and Table 4.5).
4.4.8 Interactions with DNA repair SNPs and UV exposures in females

In females we identified 6 SNPs that interacted with indoor tanning, 1 SNP that

interacted with childhood burns, 1 SNP that interacted with adulthood burns, and 5
SNPs that interacted with lifetime burns (p≤0.05) (Table 4.6). The only SNP that

was associated with increased Breslow thickness was rs2888805, which interacted

with adulthood burns; rs2888805 was also one of two SNPs in the BER pathway that
interacted with UV exposures in females (Table 4.6). All other SNPs that interacted
with UV exposure inversely modified Breslow thickness (Table 4.6). Interestingly,
we identified a SNP that interacted with childhood burns in the female analysis,
whereas we did not identify any in the male stratification or overall population

(Table 4.6). Additionally, one SNP in ERCC5 (rs7325708) was inversely associated
with Breslow thickness in females, and also interacted with adulthood burns to
inversely modify Breslow thickness (Table 4.3 and Table 4.6).

4.4.9 Comparison of interactions with UV exposures in the overall population, males,
and females

In the overall population, we identified 13 SNPs that interacted with UV

exposure to modify Breslow thickness. Of these, 6 SNPs were unique to the overall
population analysis, while 7 SNPs were also identified in either the male or female
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stratification. There was no overlap in SNPs between the male and female
stratification.

There were 10 SNPs identified in the interaction analysis for the male

stratification, 5 of which were also identified in the interaction analysis for the
overall population. All 5 of the SNPs overlapping in the male stratification and

overall population interacted with adulthood burns to increase Breslow thickness.
There were 13 SNPs identified in the interaction analysis for the female

stratification, 2 of which were also identified in the interaction analysis for the
overall population. rs4253079 interacted with lifetime burns in the overall

population to inversely modify Breslow thickness. Similarly, rs4253079 also

interacted with childhood burns and lifetime burns in females to inversely modify
Breslow thickness. rs2888805 interacted with adulthood burns in the overall
population and in females to increase Breslow thickness.
4.4.10 SNPs significant for HWE

When evaluating the control population for HWE, we found 4 SNPs that were

significantly out of HWE (p<0.01). rs4253114 (ERCC6) was significant in our SNP

association analyses for the overall population, males, and females, as well as the

interaction analysis for the overall population. rs10764889 (MGMT) was significant
in the interaction analysis for females. rs7075505 (MGMT) was significant in the
interaction analysis for the overall population.
4.5 Discussion:

78

DNA repair capacity appears to have a complex role in melanoma. Many SNPs in

DNA repair genes have previously been associated with both melanoma risk and

survival [89,94–96,114–117]. In 2013, Emmert and Kraemer issued a warning not
to underestimate NER in regard to melanoma survival [71]. They introduced the

idea that NER has a contextual role regarding melanoma; that is, diminished NER

DNA repair capacity is associated with increasing melanoma risk, while increased
NER DNA repair capacity is associated with decreased melanoma survival [71]. In

the NER pathway, we found 7 SNPs associated with Breslow thickness, and 12 SNPs

that interacted with UV exposures to modify Breslow thickness. There was only one
SNP in the NER pathway that was identified in both males and females. A previous
study showed that women have more DNA damage than men, and they have a
decreased NER capacity [73].

The contextual role of NER suggested by Emmert and Kraemer has also been

observed for the MGMT pathway [71]. The MGMT pathway repairs alkylationinduced DNA damage and has been associated with both melanoma risk and

survival [93,95,126]. In 2009, Gu et al. found that participants with a decreased

MGMT repair capacity have an increased risk for melanoma [93]. Furthermore, due
to its ability to repair damage caused by chemotherapies, increased MGMT repair

capacity is associated with chemotherapeutic resistance and lethal metastases [93].
Interestingly, one of the most consistent genes in our interaction analysis was

MGMT. We found that 5 SNPs in MGMT interacted with adulthood burns in males to
increase Breslow thickness. Conversely, we found that two different SNPs in MGMT
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interacted with lifetime burns in females to decrease Breslow thickness.

Furthermore, sex differences regarding the MGMT DNA repair pathway have
previously been reported [75,76,127].

Additionally, in our previous publication investigating DNA repair SNPs, indoor

tanning, and melanoma risk, we identified 7 SNPs that were also associated with

Breslow thickness in this study [95]. Our previous analysis was not sex-stratified, so
our ability to interpret the overlap between these two studies is limited. However,
the overlap in results does reiterate the idea presented by Emmert and Kraemer

that the role of DNA repair in melanoma is complex, and likely involved in etiology,
progression, and survival [71].

Our study has some limitations. First, we recognize that there are over 120 genes

involved in DNA repair, and our candidate gene study only included 20 of these

genes. While we covered multiple pathways known to be important in melanoma, a
more complete investigation of DNA repair SNPs in relation to Breslow thickness is
warranted. Second, the majority of the SNPs that we investigated were intronic
(>70%), which limits our ability to interpret the results in terms of functional

impact. However, in our study design, we selected tagging SNPS, which allows for

identification of a genomic region that may have functional significance. Therefore,
it is possible that the significant SNPs are in linkage disequilibrium with functional
SNPs, and should be further researched to determine functional impact.

Additionally, none of our findings were statistically significant following FDR

correction for multiple tests. However, functional evaluation of these SNPs may
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reveal biological significance. Finally, 3 SNPs that were identified in this study were
not in HWE in our control population. There are multiple reasons why SNP deviate

from HWE, and it is difficult to determine the cause in our population. Therefore, the
results for those SNPs should be interpreted with caution and validated in another
study. Finally, age is a complicated factor that we adjusted for, but could not

properly evaluate. Our study included participants aged 25-59, but the incidence of

melanoma in males increases after age 50 surpasses female risk [16]. Furthermore,
DNA repair capacity decreases with age. Taken together, we recognize that it is
likely that age also plays an important role in DNA repair as it relates to sex
differences in melanoma survival.

Our study also has multiple strengths. First, we have extensive UV exposure

information on the participants allowing for investigation of interactions with

multiple types of UV exposure. Second, the realization that UV exposure may affect
Breslow thickness and melanoma progression differently in males compared to

females may help to explain previous inconsistencies in the literature regarding UV
exposure effects on Breslow thickness and survival. Furthermore, it may help
explain the female survival advantage.

In summary, our study investigated SNP associations with Breslow thickness, as

well as SNP interactions with UV exposures that modified Breslow thickness.

Furthermore, we investigated these SNPs stratified by sex to identify factors that

may contribute to melanoma progression differently in males compared to females.

In the association analysis, we identified 10 SNPs that were associated with Breslow
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thickness. Among the 10 SNPs identified, only one SNP was associated with Breslow
thickness in both males and females. Furthermore, there was no overlap of the SNPs
that interacted with UV exposures to modify Breslow thickness in males and

females. Finally, for both the SNP associations and interactions, the majority of SNPs
we identified in males increased the odds of a thick lesion. Conversely, in females,
the majority of SNPS we identified decreased the odds of a thick lesion. These

results suggest that different genotypes in DNA repair genes contribute to Breslow
thickness, and potentially the progression of melanoma, in males compared to

females. Therefore, there may be some inherent differences in DNA repair capacity

between the sexes. Future studies investigating responses to UV exposure in males

compared to females are warranted, including further investigation of differences in
DNA repair and other pathways that have been associated with melanoma
progression and survival.
4.6 Conclusions:

We have shown that different SNPs in DNA repair genes are associated with

Breslow thickness in males compared to females. In the analysis of the overall

population adjusted for sex, we did not identify all of the SNPs that were associated
with Breslow thickness in males and females independently. Similarly, we found

that different SNPs interacted with UV exposures to modify Breslow thickness in

males compared to females. Our study suggests that there are biological differences
between the sexes regarding UV exposure, DNA repair, and Breslow thickness.

These findings may help explain the female survival advantage in melanoma and
highlight the importance of sex stratification in melanoma research.
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4.7 Tables
Table 4.1 Chi-squared analysis of sex differences in the Minnesota population
Males (n=279; 38.6%) Female (n=444; 61.4%)
p-value
n
%
n
%

Age
<30
30-39
40-49
50-59
Completed college
No
Yes
Income >$60,000
No
Yes
Missing
Breslow thickness
Thin <1mm
Thick
Breslow thickness
<1.0mm
1.00-1.99mm
2.00-3.99mm
4.00+mm
Body site
Scalp/Neck
Face
Trunk
Upper extremities
Lower extremities
Unknown
Ulceration
No
Yes
Missing
Histology
Superficial spreading
Nodular
Lentigo maligna
Other
Missing
Painful burns as child
Less than 10
Greater than or equal to 10
Painful burns as adult
Less than 10
Greater than or equal to 10
Lifetime painful burns
Less than 10
Greater than or equal to 10
Indoor tanning
Never
Ever

Bold=significant

6
36
85
152

2.2
12.9
30.5
54.5

119
160

42.7
57.3

71
206

25.6
74.4

197
82

70.6
29.4

197
53
23
6

70.6
19
8.2
2.2

22
29
126
67
30
5

7.9
10.4
45.2
24.0
10.8
1.8

255
17

93.7
6.3

39
76
180
149
235
209
138
298
354
90
354
65
18
7
13
20
109
127
170
5
396
24

8.8
17.2
40.5
33.6
52.9
47.1
31.7
68.4
79.7
20.3
79.7
14.6
4.1
1.6
2.9
4.5
24.6
28.6
38.3
1.1
94.3
5.7

117
26
15
121

41.9
9.3
5.4
43.4

186
23
9
226

41.9
5.2
2.0
50.9

164
115

58.8
41.2

287
157

64.6
35.4

198
81

71.0
29.0

121
158

43.4
56.6

161
118

57.7
42.3
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353
91
231
213
106
338

79.5
20.5
52.0
48.0
23.9
76.1

<0.01
<0.01

0.09
10
<0.01

0.02

<0.01

0.77
31

<0.01

0.11
<0.01
0.02
<0.01

Table 4.2 SNPs Associated with Breslow Thickness
Overall Population
Pathway

NER
Other
NER

SNP

Minor Allele

RFC1

rs2066786

A

G

0.41

0.65 (0.50-0.85)

<0.01

0.12

RFC1

rs2066782

G

A

0.13

0.61 (0.40-0.92)

0.02

0.45

ERCC6
ERCC4

FBRSL1
FBRSL1
ERCC6
ERCC5

rs4253114
rs1800067

rs12315756
rs1574157

rs4253114
rs876430

A
A
G

Major Allele MAF

G
G

A

0.09
0.10

1.82 (1.23-2.67)
0.56 (0.33-0.95)
0.57 (0.36-0.90)

G

0.09

2.15 (1.16-4.00)

0.02

0.9

A

G

Females

0.05

2.06 (1.00-4.26)

0.05

0.9

0.29

1.48 (1.00-2.18)

rs1574157

BER

PARP1
RFC1

rs1805414

rs2066786

G

A

0.32

0.68 (0.48-0.98)

ERCC5
ERCC5

rs4150355
rs7325708

A

G

0.37

1.52 (1.08-2.14)

Other

ERCC6

FBRSL1

rs1800067
rs4253114
rs12315756

A
G

A
A
G

G

A
G
G

A

*Adjusted for sex (in overall population only) and age
Bold=Significant in overall population
Italicized=Significant in overall population, males, and females
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0.42
0.18
0.08
0.13
0.10

0.04

0.45

A

FBRSL1

ERCC4

0.02

0.60

Males

Other

NER

0.03

0.12

0.07

G

1.60 (1.02-2.51)

<0.01

A
A

G

0.11

OR (95% CI)*

p-value* FDR Corrected
p-value*

Gene

0.05

0.68

0.02

0.67

<0.01

0.63 (0.39-1.01)

0.05

1.68 (1.01-2.78)
0.51 (0.26-0.97)

0.9

0.04

0.56 (0.29-0.81)
0.37 (0.15-0.86)

0.65

0.02
0.05
0.04

0.20
0.67
0.70
0.68
0.68

Table 4.3 Comparison of Odds Ratios between Overall Population, Males, and Females
Pathway

Gene

SNP

Overall
OR (95% CI)*

Males
OR (95% CI)*

Females
OR (95% CI)*

OR Direction

BER

PARP1

rs1805414

0.84 (0.65-1.10)

1.08 (0.74-1.60)

0.68 (0.48-0.98)



0.56 (0.29-0.81)



ERCC6

rs4253114

1.68 (1.01-2.78)



NER

Other

RFC1
RFC1

rs2066786
rs2066782

ERCC5

rs4150355

ERCC5

rs876430

ERCC5
ERCC4

rs7325708
rs1800067

FBRSL1 rs12315756
FBRSL1 rs1574157

0.65 (0.50-0.85) 0.76 (0.53-1.10)
1.82 (1.23-2.67)

2.15 (1.16-4.00)

0.61 (0.40-0.92) 0.58 (0.30-1.10)

0.63 (0.36-1.10)



1.52 (1.08-2.14)



0.83 (0.60-1.14) 1.10 (0.69-1.73)

0.63 (0.39-1.01)




0.37 (0.15-0.86)



0.57 (0.36-0.90) 0.64 (0.33-1.24)

0.77 (0.53-1.12)

0.51 (0.26-0.97)



1.37 (0.76-2.50)



1.14 (0.89-1.46) 0.84 (0.58-1.21)
1.05 (0.80-1.36)

1.48 (1.00-2.18)

1.60 (1.02-2.51)

2.06 (1.00-4.26)

0.56 (0.33-0.95) 0.80 (0.39-1.64)

*Adjusted for sex (in overall population only) and age
Bold=significant
OR Direction: Direction of the odds ratio for overall population, males, and females respectively
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Table 4.4 Multiplicative Interaction Analyses for SNPs and UV Exposures in the Overall Population
UV Exposure

Pathway

Gene

SNP

Ever Indoor Tanned

NER

ERCC6

rs4253126

BER

≥10 Adult Burns

NER

MGMT
Other

APEX1

rs1130409

ERCC6

rs6537537

TDG

rs2888805

ERCC6

rs4253226

XPC

rs3731143

ERCC6
MGMT

rs4253114

rs7905095

MGMT

rs1008982

MGMT

rs7075505

MGMT
IKBKB

rs532248
rs10958713

≥ 10 Lifetime Burns
NER
ERCC6 rs4253079
ORs, 95% CIs, and p-values adjusted for age and sex
Bold=Also identified in interaction analysis for males
Italics=Also identified in interaction analysis for females
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Minor Allele

OR(95% CI)

p-value

A

0.42(0.19-0.92)

0.03

A

2.16(1.09-4.30)

0.03

A
A
A

G
G

A

G
T

G

A
C

1.44(1.05-1.98)
1.67(1.08-2.58)
2.50(1.16-5.40)
2.10(1.06-4.18)
2.97(1.13-7.80)
1.55(1.11-2.16)
1.53(1.07-2.19)
1.38(1.01-1.87)
2.26(1.08-4.73)
1.54(1.03-2.29)
0.27(0.11-0.66)

0.02
0.02
0.02
0.03
0.03
0.01
0.02
0.04
0.03
0.04

<0.01

Table 4.5 Multiplicative Interaction Analyses for SNPs and UV Exposures in Males
UV Exposure

Pathway

Gene

SNP

Minor Allele

Ever Indoor Tanned

Other

FBRSL1
APEX1

rs4883522

rs1130409

C

4.85(1.06-22.16)

0.04

ERCC5
ERCC5

rs4150355
rs4150386

A

2.09(1.19-3.67)

0.01

BER

≥10 Adult Burns

NER

MGMT

ERCC6

rs4253226

MGMT

rs7905095

MGMT

rs4751118

MGMT

rs1008982

MGMT

rs3793903

A
C

G

A
G

A
C

MGMT
rs532248
T
ORs, 95% CIs, and p-values adjusted for age
Bold=Also identified in interaction analysis for the overall population
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OR(95% CI)
1.64(1.03-2.60)

4.02(1.21-13.35)
3.25(1.10-8.86)
1.91(1.16-3.14)
1.89(1.11-3.23)
1.84(1.10-3.09)
1.84(1.08-3.13)
1.60(1.02-2.50)

p-value
0.04
0.02
0.02
0.01
0.02
0.02
0.02
0.04

Table 4.6 Multiplicative Interaction Analyses for SNPs and UV Exposures in Females
UV Exposure

Ever Use

≥ 10 Childhood Burns

Pathway

Gene

SNP

Minor Allele

OR(95% CI)

p-value

BER

LIG1

rs13436

G

0.55(0.34-0.89)

0.02

rs1799800

A

0.48(0.24-0.93)

0.03

NER
MGMT

≥ 10 Adulthood Burns

NER

≥ 10 Lifetime Burns

NER

BER

MGMT

XPC

rs3731068

ERCC4

rs744154

ERCC4
ERCC4
MGMT

ERCC6

rs9302507
rs7897057
rs4253079

A
G

A
A
C

TDG

rs2888805
rs4253079

A

XPC

rs3731093

G

MGMT rs10764889

A

ERCC6
ERCC5

rs7325708

C
C

MGMT rs6482744
A
ORs, 95% CIs, and p-values adjusted for age
Italics=Also identified in interaction analysis for the overall population
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0.36(0.15-0.84)
0.50(0.25-0.98)
0.36(0.14-0.95)
0.63(0.29-0.99)
0.33(0.11-0.99)
3.10(1.26-7.65)
0.26(0.09-0.74)
0.33(0.12-0.93)
0.36(0.13-0.96)
0.56(0.34-0.93)
0.57(0.34-0.93)

0.02
0.04
0.04
0.05
0.05
0.01
0.01
0.04
0.04
0.02
0.03
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5.1 Abstract:
Background: Melanoma is known to be an immunogenic tumor, and exposures

such as UV and sex hormones can influence the immune system. Therefore, we

investigated immune response SNPs in association with Breslow thickness in an
attempt to further explain the female survival advantage in melanoma.

Methods: We investigated 22 immune response SNPs in cases from the

Minnesota Skin Health study. Multiple logistic regressions, stratified by sex, were
performed to determine SNP associated Breslow thickness in males and females.

Results: We identified two SNPs that were associated with Breslow thickness in

females. We also identified 3 SNPs that interacted with UV exposures to modify

Breslow thickness, 2 in females and 1 in males. There was no overlap among the

SNPs identified in males and females. None of the SNPs were significant following
FDR correction for multiple tests.

Conclusions: Different UV exposures and SNPs are important to Breslow

thickness, and potentially melanoma progression, in males compared to females.

These findings emphasize the importance of UV exposure and immune response,
along with the impact of sex on these factors, in melanoma.
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5.2 Introduction:
Melanoma is the most common cancer among young adults aged 25-29, and is

the most aggressive form of skin cancer [1]. It is well established that melanoma is

an immunogenic cancer [64]. Unfortunately, melanoma cells can evade the immune
system and the host-response is not often sufficient to abrogate tumor growth [64].
Several factors can influence the immune system, including the only established

environmental risk factor for melanoma, ultraviolet (UV) radiation [67,128]. Soluble
mediators produced by cells in the skin after exposure to UV include immune

modulators: tumor necrosis factor (TNF), IL-6, IL-10, and VDR [67,69,128]. It has

also been suggested that UV source, wavelength, frequency, and duration can all

impact the effect of UV on the immune response [67,128]. In addition, estrogen has
been associated with protection against oxidative damage, which is induced by UV
[129]. Induction of DNA repair, such as that caused by oxidative damage, is also
known to influence the immune system [128].

Endogenous exposures, such as sex steroid hormones, can also affect the

immune response [69]. The effects of estrogen, androgen, and testosterone on the

immune system are context dependent; however, in many cases, each hormone

induces its own unique response [69]. For example, estrogen increases IgG and IgM
production, while testosterone inhibits it [130,131].

Hormonal influences on the immune system may account for the fact that

females may have a more sensitive immune system than males [68]. This sensitivity
is evidenced by more vigorous humoral reactions and a higher incidence of
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autoimmune disorders in women [68]. Furthermore, estrogen is associated with
increased T lymphocyte activation and proliferation [69]. Thus, in the case of an

immunogenic tumor, a more sensitive immune system in females may be beneficial
to survival. Specific effects of hormones in melanoma immunology have been

reported. For example, estrogen, progesterone, and testosterone have the ability to
inhibit IL-8 expression which has been shown to result in slowed melanoma cell
growth [132].

Variation in UV exposures or sex steroid hormones may account for some of the

inter-individual variation in immune responses, thereby impacting the immune
response in melanoma, and potentially melanoma progression [102,111].

Importantly, UV exposures, such as indoor tanning and outdoor jobs, vary between
men and women [55]. Genetic variation, or single nucleotide polymorphisms

(SNPS), may also account for inter-individual variation in immune responses.

Howell et al. identified several SNPs in immune response genes that are associated
with Breslow thickness in melanomas [87,88,133].

Breslow thickness, which is a measurement of tumor depth in millimeters from

the granular layer of the epidermis to the deepest point, is the best prognostic

marker for melanoma [4,11]. That is, increased Breslow thickness is associated with
more aggressive melanomas, an increased likelihood of metastasis, and ultimately
increased mortality from melanoma [4,12].

Taken together, genetic variations, along with UV and endogenous exposures,

may help explain why females often have thinner lesions and better survival
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outcomes compared to males. Therefore, we hypothesized that immune response
SNPs would differentially associate with Breslow thickness in males compared to
females, and would also be influenced by UV exposures.
5.3 Methods

5.3.1 Study Population

Cases from the Minnesota Skin Healthy study, previously described, included

individuals aged 25-59 years diagnosed with melanoma between 2004 and 2007
[95,124]. Briefly, controls were frequency matched on age and sex. Of the 2268

eligible participants (cases n=1167, controls =1101), 1755 (77.4%) submitted DNA
samples for genotyping. Nine samples were removed for missing consent leaving
n=1746 (cases n=929, controls n=817) samples for analysis. For each of these
participants, we collected extensive UV exposure information from self-

administered questionnaires and phone interviews. Histopathological information
for cases was derived from the diagnostic pathology report.
5.3.2 Selection of SNPs

The selection of SNPs for this study has been previously described [95]. Briefly,

we evaluated 25 SNPs in 15 immune response genes. We used a candidate gene
approach, and the SNPs were selected based on 1) reported function in the

literature, and 2) coverage of the gene of interest based on the tagging ability of the
SNP using Haploview 4.1.

5.3.3 Genotyping Platform
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Briefly, buccal cell DNA was obtained using SCOPE® mouthwash and was

extracted using Qiagen® kits [95]. We quantitated the DNA and genotype was
evaluated by using Illumina BeadExpress GoldenGate® platform.
5.3.4 Quality Control

We removed 46 non-White participants and 7 participants with missing

phenotype index from the genotyped population (n=1693). Participants (n=261)
and SNPs (n=1) with less than a 95% call rate were removed. Analysis of Hardy

Weinberg Equilibrium (HWE) in the control population revealed that 5 SNPs were
not in HWE (p<0.01); those SNPs were removed from the analysis.

We removed all controls and cases with missing Breslow thickness from our

analysis (n=627). No additional SNPs or participants were removed due to a low call
rate (<95%). Two SNPs were removed from the analysis for minor allele frequency

(MAF) less than 0.05. The dataset for this analysis included 627 participants, leaving
252 males, 375 females, and 22 immune response SNPs. No additional SNPs or

participants in the sex-stratified analyses were removed due to a low call rate or

MAF (<95% and <0.05, respectively). The genotyping call rate for the all of the cases
(referred to as overall population) and both sex-stratified analyses was 99.9%.

5.3.5 Statistical analysis

All analyses were performed using two-sided tests and p≤0.05 was considered

significant.
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To compare differences between men and women in the population, we

performed a chi-squared contingency analysis using SAS 9.3 (SAS Institute, Cary,
NC).

We used multiple logistic regressions in PLINK 1.07 to determine which SNPs

were associated with Breslow thickness [125]. The additive genotype model was
used for these analyses. The outcome variable, Breslow thickness, was a

dichotomous variable representing thin lesions (<1.0mm) and thick lesions

(≥1.00mm). We adjusted all models for age (as a continuous variable) and, in the
overall population, we adjusted for sex.

Multiplicative interactions between SNPs and UV exposures were determined

using PLINK 1.07 [125]. We assessed interactions with indoor tanning and painful
sunburns in childhood, adulthood, and lifetime. P-values for the interactions were

determined using the likelihood ratio tests. That is, we compared the full model with
the product term for the SNP and UV exposure to the model without the product

term. We also adjusted the interaction analyses for sex (for the overall population)
and age.

5.4 Results
5.4.1 Differences between males and females in the Minnesota Skin Healthy Study
For our analysis we had more females (n=375, 59.8%) than males (n=252,

40.2%) (Table 5.1). We also noted several differences between males and females

in our population. The females in our study were younger (p<0.01) and less likely to
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be college educated (p<0.01) (Table 5.1). Females had thinner lesions than men

(p=0.02) and had more melanomas on their extremities (p<0.01). Females also had

a different distribution of histologic subtypes; that is, they had fewer lentigo maligna
melanomas (LMM) and nodular melanomas, and they had more melanomas that
were classified as ‘other’ (p<0.01) (Table 5.1). For behavioral variables, more

females had used tanning beds (p<0.01), but had less painful sunburns as an adult
and in their lifetime (p=0.02 and p=0.04, respectively) (Table 5.1).

5.4.2 SNPs associated with Breslow thickness

We identified 2 SNPs (rs1065080 and rs35874463) located in SMAD3 that were

associated with Breslow thickness in females (Table 5.2). rs1065080 was inversely
associated with Breslow thickness (OR 0.37, 95% CI=0.18-0.78), and rs35874463
was positively associated with Breslow thickness (OR 2.13, 95% CI=1.08-4.22)

(Table 5.2). There were no SNPs significantly associated with Breslow thickness in
males or the overall population. Interestingly, the direction of the odds ratios for
rs1065080 and rs35874463 seem to be opposite for males compared to females

(Table 5.2).

5.4.3 Multiplicative interactions with UV exposures

We identified 5 SNPs that interacted with UV exposures to modify Breslow

thickness. For the overall population, rs2227306 (CXCL8) interacted with childhood

burns and was associated with decreased Breslow thickness (OR 0.68, 95% CI=0.470.98) (Table 5.3). That is, a person who has the minor allele and had greater than
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10 burns as a child will have a decreased Breslow thickness compared to someone
with either the minor allele or greater than 10 burns as a child independently.

rs2227306 also interacted with lifetime burns in females and was associated with
decreased Breslow thickness (OR 0.57, 95% CI=0.35-0.93) (Table 5.3). A SNP in

IFNγ (rs2069705) interacted with indoor tanning use and was associated with

decreased Breslow thickness in females (OR 0.55, 95% CI=0.31-0.99) (Table 5.3).

The only SNP (rs3819035, IL-17A) that interacted with a UV exposure in males was

associated with increased Breslow thickness (OR 10.47, 95% CI=1.31-83.43) (Table

5.3).

5.5 Discussion
Immune response has been recognized as an important factor in melanoma

survival [64]. In fact, many of the current melanoma therapeutics exploit immune

response pathways to combat the disease [65]. It is likely that the immune system

has complicated interactions regarding sex differences in melanoma since both UV
exposures (which vary between men and women) and sex steroid hormones can

affect the immune response [7,55,128]. Our study identified 5 SNPs in 4 different

immune response genes that may play a role in melanoma progression in a sexdependent manner. Interestingly, each of the genes identified in our study have
previously been associated with melanoma, estrogen, and/or UV exposures.

We identified 2 SNPs in SMAD3 that were associated with Breslow thickness in

females. Inhibition of SMAD3 results in resistance to TGFβ-induced cell cycle arrest

in melanoma cells [134]. Interestingly, it has been shown that estrogen promotes
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SMAD3 degradation [135]. While estrogen appears to have a protective effect in

melanoma, estrogen-induced SMAD3 degradation suggests there may be a more

complicated role [136]. Furthermore, it has been shown that UV exposure decreases

expression of SMAD3. These previous findings, along with the trend we identified in
female melanoma patients, suggest a potential role for SMAD3 in a complicated and
context-dependent manner.

Our analyses revealed a SNP in CXCL8 that interacted with childhood burns in

the overall population and lifetime burns in females and decreased Breslow

thickness. UV exposure has been shown to increase secretion of CXCL8 [137]. UV
has been associated with melanoma survival; however, CXCL8 is involved in

melanoma progression and metastasis [50,53,111,138]. Furthermore, estrogen has
been shown to increase transcription of CXCL8 in breast cancer [139]. Together,

these findings suggest a complex interaction between UV exposures, CXCL8, and

melanoma progression that may be further complicated by sex-steroid hormones.
We also identified a SNP in IFNγ that interacted with indoor tanning use in

females and decreased Breslow thickness. There is evidence that UV-induced IFNγ is
involved in melanomagenesis, and promotes tumor survival [140]. However, it has
also been shown that IFNγ is necessary for VDR expression, and Vitamin D

deficiencies have been associated with increased Breslow thickness [60,128].

In males, we identified a SNP in IL-17A that interacted with adulthood burns to

increase Breslow thickness. IL-17A has previously been shown to have a tumor-

promoting role in melanoma [141]. Interestingly, UV has been shown to increase IL98

17A secretion and impact DNA repair capacity, which has been linked to both
melanoma risk and survival [95,120,142].

We recognize that our study had limitations. First, there are many immune

response genes that have been shown to play a role in melanoma, and we

investigated only a small subset of SNPs in 15 genes. However, our results

supported our hypothesis that different immune response SNPs contribute to

Breslow thickness in males compared to females. Second, our study consisted of
intronic SNPs, so it is difficult to determine the functional importance of our

findings, especially since the effect of estrogen and UV on the immune response
further complicates the interpretation. Furthermore, none of our SNPs were

significant following FDR correction. However, identification of different SNPs in

relation to Breslow thickness in males compared to females suggests there may be
some biological significance to our findings.

Our study also had multiple strengths. First, we have extensive UV information

on the participants in the study allowing us to uniquely contribute to the existing
literature on immune response SNPs and Breslow thickness. Second, the

participants in our study were ages 25-59. Since the average age at menopause is

51, it is less likely that our results were affected by decreasing estrogen levels

following menopause compared to studies with older participants. Finally, our study
may help to further explain the complicated role of UV exposures in melanoma
progression and survival.
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In summary, we identified 5 SNPs that were associated with Breslow thickness

that differ in their effect between males and females. These results indicate that

different genomic loci are important to melanoma progression in males compared
to females. It is likely that the role of estrogen and UV exposure impact these

differences. Therefore, future functional studies regarding the role of estrogen and
UV in the progression of melanoma are warranted. Furthermore, our study

highlights the importance of sex-stratified analyses in genetic epidemiology,

particularly in relation to melanoma gene-environment interactions that vary
between the sexes.
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5.6 Tables
Table 5.1 Chi-squared analysis of sex differences in the Minnesota population
Males (n=252; 40.2%)
Females (n=375; 59.8%)
n
%
n
%

Age
<30
30-39
40-49
50-59
Completed college
No
Yes
Income >$60,000
No
Yes
Missing
Breslow thickness
Thin <1mm
Thick
Body site
Scalp/Neck
Face
Trunk
Upper extremities
Lower extremities
Unknown
Ulceration
No
Yes
Missing
Histology
Superficial spreading
Nodular
Lentigo maligna
Other
Missing
Painful burns as child
Less than 10
Greater than or equal to 10
Painful burns as adult
Less than 10
Greater than or equal to 10
Lifetime painful burns
Less than 10
Greater than or equal to 10
Indoor tanning
Never
Ever

Bold=significant

6
35
77
134
107
145
66
185
183
69
18
27
116
60
26
5
231
15

2.4
13.9
30.6
53.2
42.5
57.5
26.3
73.7
72.6
27.4
7.1
10.7
46.0
23.8
10.3
2.0
93.9
6.1

34
65
149
127
201
174
114
254
301
74
8
17
92
105
149
4
335
20

9.1
17.3
39.3
33.9
53.6
46.4
31.0
69.0
80.3
19.7
2.1
4.5
24.5
28.0
39.7
1.1
94.4
5.6

110
20
13
109

43.7
7.9
5.2
43.3

154
18
8
195

41.1
4.8
2.1
52.0

145
107

57.5
42.5

242
133

64.5
35.5

181
71
107
145
146
106

71.8
28.2
42.5
57.5
57.9
42.1
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296
79
196
179
87
288

78.9
21.1
52.3
47.7
23.2
76.8

p-value

<0.01
<0.01

0.21
0.02

<0.01

0.81
26

0.03
8
0.08
0.04
0.02
<0.01

Table 5.2 SNPs Associated with Breslow Thickness
Female
Gene

SNP

Minor Allele

SMAD3

rs1065080

A

SMAD3 rs35874463

G

Major Allele MAF
G

A

OR (95% CI)*

0.13 0.37 (0.18-0.78)
0.06 2.13 (1.08-4.22)
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Male

Overall

p-value*

FDR Corrected
p-value*

OR (95% CI)*

OR (95% CI)

<0.01

0.18

1.27 (0.72-2.25)

0.72 (0.47-1.11)

0.03

0.32

0.39 (0.11-1.38)

1.29 (0.72-2.30)

Table 5.3 Multiplicative Interaction Analyses for SNPs and UV Exposures
Stratificaton
Overall
Males
Females

UV Exposure
≥ 10 Childhood Burns

≥ 10 Adulthood Burns
Ever Use

≥ 10 Lifetime Burns

Minor Allele

OR(95% CI)

p-value

CXCL8 rs2227306

Gene

SNP

A

0.68(0.47-0.98)

0.04

CXCL8 rs2227306

A

0.57(0.35-0.93)

0.02

IL-17A rs3819025
IFNγ

rs2069705
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A
G

10.47(1.31-83.43)
0.55(0.31-0.99)

0.03
0.04

CHAPTER SIX:
CONCLUSIONS AND FUTURE DIRECTIONS
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6.1 Conclusions:
Despite the fact that a female survival advantage in melanoma has been

observed for many decades, there is still no definitive explanation for why males

have poorer survival than females [28]. A common hypothesis is that males have

thicker lesions at diagnosis because they are less aware of their skin, and thicker
lesions at diagnosis are associated with increased mortality [52]. However, we

demonstrate that the female survival advantage is likely a complex phenomenon,
and cannot be reduced entirely to skin awareness.

In survival models for melanoma, sex has previously been identified as an

independent prognostic indicator for melanoma [27,31]. However, because sex is

also tightly correlated with Breslow thickness, the sex effect does not appear as an
independent prognostic indicator in some populations. This was the case in our

investigation of melanoma survival at 5-year and 15-year follow-up time points.

Despite the fact that sex was not an independent prognostic indicator in the survival
models for all of the cases (referred to as overall population), we identified different
factors contributing to melanoma survival in the sex-stratified analyses.

In particular, behavioral factors contributing to survival were different in males

compared to females. UV exposures, such as high intermittent sun exposure, were
associated with decreased hazards in males, especially in the 5-year follow-up

model. UV exposures did not significantly predict survival in females. Skin

awareness was significantly associated with increased survival for females in both

the 5-year and 15-year follow-up models. Skin awareness was borderline significant
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in the baseline model for males at 5-year follow-up, but was not included in the

adjusted models. At the 15-year follow-up, skin awareness was not associated with

male survival. Furthermore, while a higher percentage of females in the population

reported being aware of their skin, nearly 50% of men reported being aware of their
skin. Therefore, our finding that skin awareness is not predictive of survival in men
is not due to lack of reported skin awareness in the male population.

Consistent with previous studies, Breslow thickness was the strongest predictor

of survival. We also found that males with thick lesions had poorer survival than

women with lesions of the same thickness. When comparing intermediate lesions to

thin lesions and survival within sexes, we found that males had a higher hazard ratio
than females. Furthermore, our results indicated that a variable combining Breslow

thickness and sex to predict survival is a preferred model to one examining Breslow
thickness and sex individually, as measured by AIC. Finally, we found that Breslow
thickness at diagnosis was a stronger predictor of long-term survival in females

than males. These results suggested that factors contributing to Breslow thickness
might also vary between males and females.

To date, there are no other studies that investigate the multiple factors that may

contribute to Breslow thickness, especially in a sex-stratified analysis. We evaluated
other histopathological factors in the Breslow thickness models, and found the same
associations in males and females. These results are difficult to interpret as all

histopathological factors are markers of melanoma progression, and are likely

collinear with Breslow thickness rather than explanative of Breslow thickness.
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Opposite to the survival analysis, we found that UV exposures were associated

with decreased odds of a thick lesion in females, but were not associated with

Breslow thickness in males. Some of the UV exposure effect may be due to the

correlation of skin awareness with UV behaviors; however, in a baseline analysis of

females who reported being unaware of their skin, UV exposures were still inversely
associated with Breslow thickness. This suggests that UV exposure effects on
survival were encompassed by the Breslow thickness variable in our survival

models, whereas UV exposure influenced male survival independent of Breslow

thickness. Therefore, it is likely that UV exposure impacts melanoma progression

and survival differently in males compared to females. Furthermore, skin awareness
was associated with decreased Breslow thickness in females, but not in males. In

fact, we did not identify any behavioral factors associated with Breslow thickness in
males.

To evaluate the self-reporting of skin awareness, we performed a chi-squared

contingency analysis, and found that skin awareness was similarly associated with
college education, indoor tanning, and ever had a painful burn in both males and
females. This finding suggests that the lack of association between Breslow

thickness and skin awareness in males is not due to differences in reporting of skin
awareness between the sexes. Overall, our findings suggest that male melanomas
are inherently more aggressive and may be biologically distinct from female

melanomas. The importance of skin awareness and SSE in early detection of

melanoma should not be minimized; however, its limitations, particularly in males,
should be recognized.
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It is clear that UV exposure plays a complex role in melanoma initiation,

progression, and survival, and it has impacts on multiple systems in the body that
are also important to melanoma including the immune system and DNA repair

[71,128]. One way to examine inter-individual variations in immune response and
DNA repair is via investigation of SNPs located in genes associated with those

processes [73]. Furthermore, it is evident that sex steroid hormones can influence

UV exposure response, immune response, and DNA repair [68,69,73,128,143]. One

way to control for sex-steroid hormone interactions with these systems is to stratify

analyses by sex. Therefore, we investigated SNPs in DNA repair and immune

response genes and their associations with Breslow thickness in a sex-stratified
analysis. To factor in UV exposures, we investigated SNP interactions with UV
exposures that modify Breslow thickness in a sex-stratified analysis.

In the analysis of DNA repair SNPs, we identified 3 SNPs associated with Breslow

thickness in males and 7 SNPs associated with Breslow thickness in females. Of

these SNPs, there was only one that overlapped between sexes. We also identified
10 SNPs in males that interacted with UV exposures to modify Breslow thickness,
and 13 SNPs in females that interacted with UV exposures to modify Breslow

thickness. Of these SNPs, there were no SNPs that overlapped between males and
females. While none of the SNPs were significant following FDR correction, it is

important to consider the biological relevance. The lack of overlap in SNPs between
males and females, especially those that interacted with UV exposures, suggest that
DNA repair responses to UV exposure may vary between men and women.
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Importantly, these variations appear to affect Breslow thickness, which indicates
that melanoma progression is impacted.

In the analysis of immune response SNPs, we identified 2 SNPs that were

associated with Breslow thickness in females. We did not identify any SNPs that
were associated with Breslow thickness in males. We identified 3 SNPs that

interacted with UV exposures to modify Breslow thickness. Of these, 1 SNP modified
Breslow thickness in males, and 2 SNPs modified Breslow thickness in females.

There was no overlap in immune response SNP associations between the sexes.
Similar to the DNA repair SNPs, none of the SNPs were significant following

correction for FDR. However, these differences in males and females suggest a

potential difference in the role of immune response in the progression of melanoma,
especially following UV exposures.

6.2 Future studies:

We investigated the association of DNA repair and immune response SNPs with

Breslow thickness, along with their interactions with UV exposures to modify

Breslow thickness, in a sex-stratified analysis. DNA repair has been shown to play a

role in melanoma from melanomagenesis to metastasis and survival [71]. Therefore,

it would also be beneficial to investigate DNA repair SNP associations in melanoma

risk and survival in a sex-stratified analysis. Similarly, melanoma is known to be an

immunogenic tumor, highlighting the importance of investigating immune response
SNP associations in melanoma risk and survival in a sex-specific manner [64,65].

Furthermore, investigating DNA repair and immune response SNP interactions that
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modify melanoma risk and survival in males compared to females may provide
more insight to the sex-specific role of UV exposure in melanoma.

To further investigate the SNPs we identified, they should be functionally

evaluated. That is, we should determine whether the SNPs are in linkage

disequilibrium with any functional SNPs. Furthermore, fine mapping studies

investigating heritability and disease outcomes may provide functional clues.

Finally, epigenetic changes, such as promoter methylation, may be associated with
SNPs identified in our studies. In particular, MGMT promoter methylation is

associated with increased therapeutic response, and we identified multiple SNPs in

MGMT that were associated with Breslow thickness, especially in males [72,76,127].

Therefore, investigating MGMT promoter methylation and SNP associations would
provide functional insight and perhaps identify sex differences in therapeutic
response.

Interestingly, while ERβ is expressed in melanoma, and high expression has been

associated with decreased Breslow thickness, there is very little known about the

role of ERβ in melanoma etiology and progression [39]. Therefore, it is important to
develop functional studies investigating ERβ in melanoma. We suggest that

melanoma cells be treated with ERβ agonists and antagonists to evaluate the in vitro
effects of ERβ on proliferation and invasion, along with evaluation of downstream

effectors including genomic and non-genomic events. Furthermore, animal studies
investigating the interaction between UV exposures and ERβ are important to
learning about the role of UV exposures in the female survival advantage.
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Similarly, the role of GPER in melanoma is unknown. Our preliminary data

suggests that GPER is, in fact, expressed in melanoma tissues. However, future
studies investigating its expression in males compared to females are needed.

Following identification of GPER in melanoma tissues, the functional role of GPER in
melanoma should be investigated.

6.3 Overall conclusions and perspectives:
Our study suggests that the explanation for the female survival advantage in

melanoma is complex. Behavioral differences in males and females, such as UV

exposure, appear to interact with biological differences to impact the progression of,
and ultimately the survival from, melanoma. These findings have multiple

implications in melanoma. With the importance of behavioral and biological

interactions demonstrated, it is imperative that future studies of melanoma consider
investigating melanoma risk, progression, and survival in a sex-stratified manner.

Furthermore, it is necessary to determine the impact of UV exposures on melanoma

risk, progression, and survival in males compared to females to fully understand the
role of UV exposure in melanoma. Notably, these distinctions could be instrumental
in personalized treatment of melanoma and therapeutic development.

Furthermore, these findings have implications for other diseases and

epidemiological studies as a whole. First, there are many other diseases with

evident sex differences that may benefit from sex-stratified analyses including
cardiovascular diseases, lung cancer, and autoimmune disorders [36,68,144].

Second, epidemiological studies are generally stratified by population [145]. For
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example, African Americans may be excluded from a study investigating

cardiovascular disease limiting the study to Caucasians. This is because African

Americans are known to be a genetically distinct population with different incidence
and outcomes in cardiovascular disease [145]. Therefore, it is assumed that there

are biological differences between the populations that would confound the results.

Similarly, there are biological differences between males and females that confound
results, as shown in our study. However, in the past, epidemiological studies adjust
for sex in the model rather than stratifying by sex. Importantly, it is likely that the
lack of sex-stratification is confounding results, even in epidemiological studies of
diseases that do not have evident sex differences.
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